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OBJECTIVES OF PRESENT WORK 
 Drug is incompletely absorbed from GIT, thus its oral bioavailability is only about
50%. The incomplete absorption is mainly due to its lower lipid solubility. Literature
shows that moderately polar drugs with low molecular weight can penetrate through
the nasal  mucosa to the greater  extent  than through gastrointestinal  tract,  thus the
present work is aimed at studying the nasal permeation of  Drug and improving its
nasal permeation by the addition of penetration enhancer  chitosan so that Drug could
be successfully administered by nasal route. 
However  one  shortcoming  associated  with  the  nasal  route  is  high  mucocilliary
clearance and low retention of the drug for short period of time. Thus an attempt has
been made to increase the retention time of the drug by incorporating chitosan, which
shows  temperature  mediated  phase  transition  in  presences  of  sodium  beta-
glycerophosphate and possess mucoadhesive property as well.
Present investigation was planed with following objectives
• To find the applicability of  chitosan in  the  formulation of  phase transition
system.
• To study the effect of chitosan as nasal permeation enhancer.
• To study the mucoadhesive property of chitosan.
CH. I    1. INTRODUCTION 1,2,3,4,5,6
Drugs have been administered nasally for therapeutic and recreational purposes since
ancient times. Psychotrophic drugs and halucinogens were snuffed for their purposes
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by the Indians of South America,  and this practice is currently widespread among
abusers  of  cocaine  and  heroine.  Traditionally  the  nasal  route  has  been  used  for
delivery of drugs for local treatment of diseases such as nasal congestion, allergy and
infections. The interest in and importance of the systemic effect of drugs administered
via  the nasal route have expanded over recent decades. Nasal administration offers an
interesting  alternative  for  achieving  systemic  drug  effects  to  the  parenteral  route,
which can be inconvenient, as parental route can be undesirable or impractical if a
drug is intended for the treatment of chronic disease or oral administration, which can
result in unacceptably low bioavailabilties because of significant degradation in the
GIT due to enzymatic or acidic environment or metabolized to a high degree via the
first pass effect in the liver. The non parenteral routes suitable for self administration
of drug in an ambulatory settings includes nasal, buccal, pulmonary and transdermal.
The  nasal  epithelium  is  a  highly  permeable  monolayer,  the  submucosa  is  richly
vascularised and hepatic first pass metabolism is avoided after nasal administration.
Other attractive feature includes the rather large surface area (180 cm2 because of the
presence of large no. of microvilli) of the nasal cavity and the relatively high blood
flow,  which  promotes  rapid  absorption,  porous  endothelial  membrane  and  highly
vascularised  tissue  providing  an  attractive  site  for  rapid  and  efficient  systemic
absorption,  furthermore,  self  medication  is  easy  and  convenient.  Currently,  nasal
administration is used therapeutically for the systemic absorption of drugs in a variety
of indications, including sumatriptan for migraine7, the antidiuretic desmopressin for
the treatment of diabetes insipidus8 and oxytocin for  the stimulation of breastmilk
ejection.  Other  drugs  still  in  the  research  and  development  pipeline,  which  have
potential  for  administration  nasally  includes  vitamin  B12  or  hydroxocobalamine,
various  benzodiazepines  and  the  dopamine agonist  apomorphine  for  patients  with
parkinsons
                                                                                                                             
                                                                                                                                    
 
2
Figure 1: Various mucosal routes as potential pathway to by pass the
hepato-gastrointestinal first pass elimination associated with oral administration.
1.1  Advantages of nasal drug delivery: 6,9,10,11
Nasal  Drug  delivery  provides  a  viable  alternative  for  the  administration  of  many
pharmaceutical  agents.  Some of  the  major  advantages  offered  by  the  nasal  route
include:
• Rapid absorption into the systemic circulation.
• Rapid onset of therapeutic action.
• Elimination of first pass hepatic metabolism.
• Avoids degradation of drugs in the gastrointestinal tract, resulting from acidic
or enzymatic degradation.
                                                                                                                             
                                                                                                                                    
 
3
Nasal 
epithelium
First pass
Mucosal Delivery
Ocular Delivery
Nasal Delivery
Vaginal delivery
Nasolacrimal drainage 
system
Nose
  Buccal Sublingual 
  Gingival
Respiratory 
membrane
Oral 
mucosa
 Rectal 
mucosa 
Vaginal 
mucosa
Systemic 
Circulation
Oral Delivery
Portal circulation
     Liver
   Target Tissue
Pharmacological 
response
G.I. Absorption
Distribution
  Pulmonary delivery
Rectal delivery 
(lower half)
• Rich vasculature and highly permeable  structure  of  nasal  mucosa results  in
higher bioavailability thus require lower doses of drug. 
• More flexible dosing schedule and control of drug effects
• No pulmonary toxicity.
• Less drug degradation.
• Easily accessible, non-invasive route, thus better patient’s compliance.
• Self-medication is possible through this route.
• Offer lower risk of overdose.
• Easy accessibility to blood capillaries.
• Direct transport into systemic circulation and CNS is possible.
• Does not have any complex formulation requirements.
         Disadvantages of nasal drug delivery: 6,9,10,11
• High  molecular  weight  compounds  cannot  be  delivered  through  this  route
(mass cut off ~1 K dalton).
• Large  mucociliary  clearance  of  the  nasal  mucosa  may  cause  the  poor
absorption of certain drugs.
• Some therapeutic agents may be susceptible to partial degradation in the nasal
mucosa or may cause irritation to the mucosa.
• Adversely affected by pathological conditions.
• Volume that can be delivered into the nasal cavity is restricted to 25-200 µl.
• Large interspecies variability is observed in this route.
• Limited understanding of mechanism and less developed model at this stage.
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 Overview of nasal mucosa 1,2,3,12,13,14
 Anatomy and function
Breathing and olfaction are the prime functions of the nasal cavity in humans and
animals. Physiologically, the structure and function of this cavity are also related to
the resonance of produced sounds, the filtration of particles, mucociliary clearance,
immunological activities, and heating and humidification of the inspired air before it
reaches the lungs.1
The  nasal  passage  which  runs  from  nasal  vestibule  (i.e.  nasal  valve)  to  the
nasopharynx has a depth of approximately 12-14 cm. The nasal septum divides the
nasal cavity into two unequal cavities. The septum consists mostly of cartilage and
skin and therefore, the penetration of drug is low. The nasal cavity can anatomically
be  segregated  into five  different  regions,  nasal  vestibule,  atrium,  respiratory  area,
olfactory  region,  and  the  nasopharynx  as  shown in  Figure  2.  The  vestibular  area
serves as a baffle system, and its surface is covered by a common pseudo stratified
epithelium where long hair may provide the function of filtering airborne particles.
Secondly the olfactory region  which is  located on the roof  of  the nasal  cavity in
humans and forms about 10% of the total area of nasal cavity.  Thirdly respiratory
region consists of the inferior, middle and superior turbinate attached to the lateral
wall, and is considered as major site of drug absorption into the systemic circulation.
The respiratory area has a surface lined by a pseudo stratified columnar epithelium
and  is  normally  covered  by  a  dense  layer  of  mucus.  These  cells  are  covered  by
microvilli and the major part of these cells is also covered with cilia. Large number of
microvilli results in increased surface area of 180 cm2  responsible for relatively high
absorptive capacity of the nasal cavity, whereas ciliated cells propel the mucus layer
in a direction from the anterior towards the posterior part of the nasal cavity. Cilia
beat with a frequency of 1000 strokes per minute and the mucus is transported at the
rate of 5 mm per minute. The mucus layer is renewed every 15-20 min and hence the
formulations applied to human nasal cavity are cleared with a clearance half-life of 15
minutes.
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Figure 2 : Saggital section of the human nasal cavity, showing the nasal vestibule
(A), Atrium (B), Respiratory Area: Inferior (C1), Middle (C2) and Superior (C3)
turbinate, Olfactory region (D) and Nasopharynx (E).1.3.2 Nasal Epithelium 12
The nasal cavity is highly vascularised and its membrane can be classified into two
types:  olfactory and non-olfactory.  The olfactory epithelium is  a  pseudo stratified
columnar structure. It consists of specialized olfactory cells, supporting cells, serous
and mucosal  glands.  The nonolfactory part  is  a  vascular  membrane.  Its  surface is
covered  by  ciliated  pseudo  stratified  columnar  epithelium.  Numerous  groups  of
microvilli can be seen microscopically among the group of cilia. All microvilli are of
short club like appearances and there are approximately 500 microvilli on the surface
of each ciliated cell. These cells with microvilli are called goblet cells. Another type
of epithelial cells are observed in the free surface of the mucous membrane. They are
rounded or elongated in shape and rough on the surface. These cells are defined as
squamous cells.
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Figure 3 : Trans membrane electron microscopic view of various cell types in the
nasal epithelium.
 Nasal Secretions 9,12
The composition of  the  nasal  secretions  is  complex  and  consists  of  a  mixture  of
secretary  materials  from the goblet  cells,  nasal  glands,  and lacrimal  glands  and a
transudate from plasma. In  a clean, noninfected, nonallergic, and nonirritated nose,
the mucosa is  covered by a thin layer  of  clear  mucus which is  secreted from the
mucous  and  serous  glands  in  the  nasal  mucosa  and  sub  mucosa.  A  total  of
approximately 1500-2000 ml of mucus is produced daily,  which contains 90-95 %
water,  1-2 % salt and 2-3 % mucin. The mucus has a two-layer composition: The
watery (sol) layer  is located immediately adjacent to the mucosal  surface,  and the
mucous (gel) layer, which is more superficial. Normal Nasal secretions contain about
150 mEq/L of sodium, 40 mEq/L of potassium, and 8mEq/L of calcium as well as
about 600 mg % of proteins, including 57 mg % of albumins and 133 and 50 mg % of
immunoglobulin A (IgA) and G (IgG) respectively.
In  addition  to  mucous  glycoproteins,  nasal  secretions  contain  a  variety  of  other
proteins,  lysozymes,  enzymes,  Ig  A,  Ig  E,  Ig  G  and  albumins,  kallikrein  like
substances, protease inhibitor, prostaglandins, as well as serum proteins like gamma
A-globulin, gammaG -globulin, albumin and siderophilin.
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The functions of mucus include:
 Acts as a retainer for the substances in the nasal duct
 Behaves as an adhesive
 Has water holding capacity
 Transports particulate matter
 Exhibit surface electricity activity
 Protect the mucosa
 Acts as mesh with permeability
 Allows heat transfer
 Nasal mucociliary clearance 13,15
Nasal mucociliary clearance is normal defense mechanism of the nasal cavity that
clears mucus as well as substances adhering to the nasal mucosa (bacteria, allergens,
and  so  on)  and  drains  them  into  the  nasopharyx  for  eventual  discharge  into  the
gastrointestinal tract. There are approximately five ciliated cells for each mucous cell,
with an average  of  200 cilia  extending from every ciliated cell  on the  surface  of
pseudo stratified columnar epithelium. An individual cilium is approximately 5 µm in 
length and 0.2 µ  in diameters, which moves at  a frequency of about 20 beats/sec.
nasal clearance proceeds at an average rate of about 5-6 mm/min. Normal mucociliary
transit time in humans has been reported to be 12-15 min. Transit times more than
30 min are considered to be abnormal,  and are indicative of impaired mucociliary
clearance. Formulations administered to the human respiratory epithelium have been
found to be cleared from the nasal cavity in ~ 21 min by mucociliary clearance.
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Figure  4 :  Mucocilliary clearance of the nose
                    
 Nasal Enzymes  9,12,16
Nasal  mucus  acts  as  enzymatic  barriers  to  the  delivery  of  drugs  because  of  the
presence  of  a  large  number  of  enzymes.  They  are  cytochrome  P-450  dependent
monoxygenases,  Lactate  dehydrogenase,  oxydoreductases,  hydrolases  acid
phosphatase  and  esterase,  NAD+  dependent  formaldehyde  dehydrogenases  and
aldehyde dehydrogenase;  leucine amino peptidase, phosphoglucomutase,  glucose-6-
phosphate dehydrogenase,  aldolase,  lactate dehydrogenase,  isocitric dehydrogenase,
glutamic   transaminase and steroid hydroxylases. These enzymes are responsible for
the degradation of drugs in the nasal mucosa and results in creation of a pseudo-first
pass effect, which hampers the absorption of drugs. In spite of these hurdles, the nasal
route is still considered to be superior to the oral route. The level of amino-peptidase
present is much lower than that in the gastrointestinal tract. Various approaches have
been used to  overcome these degradations.  These include the use of  protease and
peptidase  inhibitors  such  as  bacitracin,  amastatin  etc.  Apart  from  using  enzyme
inhibitors,  efforts  are  focused  on  designing  prodrug  to  increase  the  stability  and
permeation of compounds
Although enzymes are known to exist in the nasal tissues, they do not appear to have
a significant effect on the extent of absorption of most compounds except peptides.
For  example,  the  nasal  bioavailability  in  animal  and  man  of  progesterone,
testosterone, estradiol, naloxone, propranolol and butorphanol is almost 100 % of that
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Figure  4 :  Mucocilliary clearance of the 
nose
of  the  intravenous  administration.  The  above  drugs  have  an  oral  bioavailability
ranging from 20-30 % for propranolol to 0 % for the other mentioned drugs. These
low oral bioavailabilities are due to the extensive metabolism of the compounds in the
gastrointestinal tract. The nasal administration of these compounds results in complete
absorption because the level of the enzymes in the nasal tissue (mg/g) is very low and
can be easily saturated with the drug.
 Nasal pH 9,12
The  normal  pH  of  the  nasal  secretions  in  the  adult  ranges  approximately  from
5.5 to 6.5, whereas in infants and young children it ranges from 5.0 to 6.7. During
acute rhinitis, acute sinusitis, and in the more acute phases of allergic rhinitis, the pH
of the nasal secretions was found to be on the alkaline side and then shifted back to
acidity, when the stage of clinical resolution was reached. The cause of nasal pH can
be  altered  by  the  influence  of  cold  or  heat.  Cold  air  produces  a  drift  towards
alkalinity,  whereas  heat  yields  a  drift  toward  acidity.  Greater  drug  permeation  is
usually achieved at a nasal pH that is lower than the drugs pKa because under such
conditions the penetrant molecules exist as unionized species. Because the pH of the
nasal  cavity can alter  the pH of the formulation and vice-versa,  the ideal  pH of a
formulation should be within 4.5-6.5.
 Nasal blood flow12,17
The nasal  mucosa is highly vascular.  The surface of epithelium is supplied with a
dense network of erectile cavernous tissue which is particularly well developed over
the  turbinate  and  septum.  The  presence  of  venous  sinusoids  and  arteriovenous
anastomosis gives the nasal mucosa the distinction of being a highly permeable site.
The arterial blood supply to the nasal cavity is derived from both the external and
internal  carotid  arteries.  The  terminal  branch  of  the  maxillary  artery  supplies  the
sphenopalatine artery which in turn supplies the lateral and medial wall of the nasal
chamber.  The anterior  and  posterior  ethmoid  branches  come from the  ophthalmic
artery,  which  is  a  branch  of  the  carotid  artery.  These  vessels  supply the  anterior
portion of the nose. Additionally, twigs from the facial artery supply the vestibule and
anterior  portion of the septum. Some vessels from the greater  palatine artery pass
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through the incisive canal  of the palate to reach the anterior part of the nose. The
veins  of  the nasal  cavity drain into the sphenopalatine foramen and then into the
pterygoid  plexus.  Some other  veins  accompany the  ethmoid  arteries  and  join  the
superior ophthalmic vein. Veins which are anterior in the nose drain into the facial
vein.  The richly supplied vascular nature of the nasal mucosa, coupled with its low
barrier to drug permeation, makes the nasal route of administration attractive for a
number of drugs, both peptide and nonpeptide drugs. In addition, the olfactory region
provides a potential advantage whereby a drug may be exposed to neurons that may
facilate its access into the cerebral spinal fluid, when administered nasally. 
Constriction of the blood vessels would decrease blood flow and blood content in the
nasal  mucosa,  whereas  vasodilation  would  yield  the  opposite  response.  The
penetration of the drug through the sinus mucosa is partly influenced by the blood
flow in the region under normal and pathological conditions.
Figure 5 : Diagram showing highly vascularised nasal cavity
.
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 Nasal Pathophysiology 12
Diseases  such  as  the  common  cold,  rhinitis,  atropic  rhinitis,  nasal  polyposis  are
usually  associated  with  mucociliary  dysfunction,  hypo  and  hyper  secretions,  and
irritation of the nasal mucosa, which can influence drug permeation and subsequently,
the therapeutic efficacy of the drugs administered nasally.  In  some subjects with a
severe nasal allergy, an excessive response of the secretary system to irritants could
wash away the drug solution administered into the nasal cavity before the drug is
absorbed by the nasal membrane.
 Tight Junction (TJ) 10,18
TJs are structure that form a barrier between adjacent epithelial cells with a narrow
band just beneath the apical surface, and are found in all tissues of the body. They
perform two vital function: as a barrier or gate to the movement of molecule between
cells  in  the  paracellular  space,  and  as  a  fence  to  prevent  diffusion  of  integral
membrane proteins between the apical and basolateral surfaces, thus preserving, for
example, the special function of receptor mediated endocytosis at the apical surface
and exocytosis at the basolateral surface. High molecular weight drugs need to pass
through TJ barriers in order to become systemically available and to move to their site
of action as part of the bodies normal activity, TJs selectively modulate paracellular
permeability by opening and closing in response to various signals inside and outside
of cells, including responding to cytokines, immune cells, nutrients, calcium depletion
and  lipid  modifying  agents.  TJs  consist  of  a  variety  of  integral  membrane  and
peripheral,  or  associated,  proteins,  which  are  anchored  in  the  membranes  of  two
adjacent cells and interact across the paracellular space by noncovalent forces .In the
cytoplasm, TJ membrane proteins interact with scaffold proteins to connect them with
the cellular cytoskeleton and various signal transduction and transcriptional pathways
involved in the regulation of TJ function. Dysregulation of TJ function occurs in a
variety  of  diseases,  particularly  inflammation,  cancer  and  CNS pathologies  where
normal tissue permeability and cell adhesion interactions are altered.
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Transmembrane Proteins of the Junctional Complex
Epithelial  cells  characteristics  of  the  nasal  mucosa,  like  other  tissues,  are  joined
together by TJs. The closely associated adherens junction is found on the basolateral
side  but  is  not  circumferentially  continuous,  like  the  TJ,  and  therefore  does  not
contribute significantly  to  the epithelial  barrier  properties.  The cell  membranes  of
adjacent cells are intimately connected by proteins of the junctional complexes to an
extent that one can measure a significant transepithelial electrical resistance (TEER).
Freeze fracture electron microscopy (but not thin sections) visualises TJs as a network
of strands that  appear  as rows of  10 nm particles  within the plane of  the plasma
membranes of the neighbouring cells. These strands have been predicted to contain
pores  that  dynamically  open  and  close.  Three  major  types  of  integral  proteins
comprise  TJs:  Occludin,  claudins  and  junction  adhesion  molecules  (JAM)  These
junctional proteins are involved in cell-cell adhesion and are dynamically regulated .A
group of scaffolding proteins, including a family of zonula occludens (ZO) proteins,
connect  TJs  and  AJs  to  the  cytoskeleton  and  mediate  intracellular  signaling.  A
number of additional cytosolic and nuclear proteins interact directly or indirectly with
TJ scaffolding proteins and are also involved in regulating diverse functions including
paracellular permeability cell polarity etc claudins may be the single most important
component of the TJ because they alone can form TJ strands. Claudins play a key role
in regulating ion flux as major components of paracellular channels,where indivisual
claudins function as ion–specific pores. E-cadherin is a 120-k Da a transmembrane
protein, which is a constituent of the AJ. It is important for initiating and maintaining
cell-cell contacts and is required for the formation of and maintenance of TJs.
Chitosan has been shown to disrupt intercellular TJs, thus increasing permeability by
translocation  of  TJ  proteins  from  the  membrane  to  the  cytoskeleton.  Immuno
fluorescent  localization  of  ZO-1  revealed  loss  of  membrane  associated  ZO-1  and
occludin from the cytosolic and membrane fractions into the cytoskeletal fraction.
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Drug Absorption Through the Nasal Mucosa 13,20 
The first  in  the  absorption of  drugs  from the nasal  cavity  is  passage  through  the
mucus.  Small  uncharged  particles  easily  pass  through  this  layer.  However  larger
particles may find it more difficult to cross. Mucin the principle protein in the mucus
has the potential to bind solutes, hindering diffusion. Additionally structural changes
in the mucus layer  are possible as a result of environmental changes, (i.e. pH and
temperature). After a drug passage through the mucus, there are several mechanisms
for absorption through the mucosa.
 Mechanism of drug absorption:
As seen with the other epithelium in the body, absorption across nasal epithelium can
occur by one or combination of mechanisms. Following two mechanisms have been
considered  predominantly.  The  first  mechanism  involves  an  aqueous  route  of
transport, which is also known as the paracellular route. Drugs are believed to pass
through the epithelium via the gaps or pores between the cells (the tight junction).
This  route  is  slow and  passive  and  this  pathway is  especially  suited  for  smaller
hydrophilic molecules. Although, the tight junctions are dynamic structures that can
open and close to certain extent, the size of these channels is less than 10 Ao. There is
an inverse log correlation between intranasal absorption and the molecular weight of
water-soluble compounds. Hence, the paracellular route will be less efficient for large
molecules and is dependent upon the molecular weight of the drug with a general
molecular size cut – off of 1000 Dalton.
The second mechanism involves transport through a lipoidal route that is also known
as the transcellular process and is responsible for the transport of lipophilic drugs by
an efficient concentration dependent passive diffusion process, by receptor or carrier
mediation and by vesicular transport mechanism. This pathway is especially suited for
small lipophilic molecules or large molecules.
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Figure 6 :  Diagram showing the physical model for transmembrane
permeation  across a mucosal membrane
Intracellular axonal transport of drugs through olfactory neuron cells is also one of the
mechanisms, responsible for transport of drugs primarily to the olfactory bulb. The
olfactory epithelium is known to be a portal of entry for substances into the central
nervous system (CNS) and peripheral circulation. The transport of drugs across the
nasal membrane and into the blood stream may involved either passive diffusion of
the drug molecules  through the pores  in  the  nasal  mucosa  or  some form of  non-
passive transport. The can enter into the CNS when administered in the nasal cavity, a
proportion is transported through the olfactory lobes of the brain, or in some cases,
further into the parenchyma of the brain. It has been show that the rate and degree of
transport and deposition are highly dependent on the physicochemical properties of
the drugs,  especially molecular  weight  and the lipophilicity.  Drug transport  routes
from nasal cavity are depicted in Figure 7. When drugs are administered nasally the
drug will normally be rapidly cleared by the mucocilliary mechanism. Some of the
drug  will  be  absorbed  into  the  blood  stream  from where  it  reaches  the  systemic
circulation directly and subsequently is  eliminated from the blood by crossing the
blood brain barrier, but can also be eliminated from CSF into the brain.
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Figure7:possible route of transport of drug administered nasally
1.8.2 Factors influencing the absorption of drugs through nasal epithelium9,17,21
Factors  influencing  absorption  are  related  to  nasal  physiology,  physicochemical
characteristics of drugs and formulation aspects.
I. Biological:
A) Structural features
B) Biochemical changes
C) Physiological factors
• Blood flow
• Nasal secretions
• pH of the nasal cavity
• Mucocilliary clearance and ciliary beat frequency
   D) Pathological conditions
   E) Environmental factors
• Temperature
• Humidity
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Figure 7 : Possible route of transport of drug administered nasally
II. Physicochemical properties of drugs
• Molecular weight
• Size
• Solubility
• Lipophilicity
• Pka and partion coefficient
III. Physicochemical properties of formulation
• Dosage form
• Viscosity
• PH and mucosal irritancy
• Osmolarity
• Volume of solution applied
IV. Device related
• Particle size of the droplet/powder
• Size and pattern of disposion
       
Physiological factors include firstly mucociliary clearance is one of the major factor
responsible for the clearance of the drugs from the nasal cavity, it involves combined
action of mucus layer  and cilia,  tips of cilia  are in contact  with and transport  the
superficial  viscoelastic  mucus layer  towards  nasopharynx while less viscous lower
layer of mucus is relatively stationary. Secondly broad ranges of metabolic enzymes
are present in the nasal mucosa. This can limit bioavailability of nasally administered
drugs; however level of activity of these enzymes is lower as compared to that found
in GIT and liver. Moreover pathological conditions like rhinitis, common cold can
also affect  absorption of  drugs  from nasal  cavity.  pH of  nasal  cavity also affects
permeation  of  drug.  A change  in  the  pH of  mucus  can  affect  the  ionization  and
increase or decrease the permeation of drug, depending on the nature of the drug.
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Physicochemical characteristics of drugs:
Various physicochemical characteristics of drug can also affect nasal absorption of
the drug.
Molecular Weight and Size: 13,17,20
Extent of the absorption of the drug depends on molecular weight particularly for
hydrophilic compounds. Nasal route is suitable for efficient delivery of drugs up to
1000 Daltons. Absorption reduces the significantly if the molecular weight is greater
than 1000 Daltons except with the use of penetration enhancers. It has been reported
that a good linear correlation exists between the log percentage drug absorbed nasally
and the log molecular weight of water soluble compounds suggestion the participation
of aqueous channels in the nasal absorption of water soluble molecules.
It has been reported that particle size greater than 10 µm are deposited in the nasal
cavity. Particles that are 2 to 10 µm can be retained in the lungs, and particles of less
than 1 µm are exhaled.
Solubility and Dissolution: 
Drug solubility is a major factor in determining absorption of drug through biological
membranes.  It  not  only  limits  the  drug  absorption  per  se,  it  can  also  limit  a
formulator’s ability to formulate a product if the drug is not sufficiently soluble in the
desired vehicles. As nasal secretions are more watery in nature, a drug should have
appropriate  aqueous  solubility  for  increased  dissolution.  Particles  deposited in  the
nostrils need to be dissolved prior to absorption. If  the drug remains as particles in
nostrils,  or  if  they  are  cleared  away  from the  nasal  cavity,  one  may not  observe
absorption of the drug.
Chemical form:
The chemical form in which a drug is presented at the nasal mucosa can be important
in determining its absorption. For example, conversion of a drug into a salt or ester
form can alter  its  absorption.  This  phenomenon is  associated with the increase  in
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lipophilicity  following  esterification,  which  increased  the rate  and  extent  of  nasal
absorption.
Partition coefficient and pKa:
Jiang et al. (1997) conducted a study to find out the quantitative relationship between
the physiochemical  properties  of drugs and their  nasal  absorption, using diltiazem
hydrochloride and paracetamol as model drugs. The result showed that a quantitative
relationship existed between the partition coefficient and nasal absorption constant.
As per the pH partition theory, unionized species are absorbed better compared with
ionized species and same holds true in the case of nasal absorption. The extent of
absorption is PH dependent, being higher at a pH lower than the pKa and decreases
beyond the pKa. 
A  relationship  between  the  lipophilicity  and  absorption  rate  constant  of  mucosal
absorption of progesterone was shown by Corbo et. al. In general, the authors found
that  the  nasal  absorption  increase  with  the  lipophilicity  of  the  permeant.  Various
studies indicate that the drug concentrations in the cerebrospinal fluid (CSF) rise with
an increase in lipophilicity or partition coefficient of the drugs. The nasal absorption
of weak electrolytes such as salicylic acid and aminopyrine was found to be highly
dependent on their degree of ionization. Although for aminopyrine,  the absorption
rate increased with the increase in pH and was found to fit  well to the theoretical
profile,  substantial  deviations  were  observed  with  salicylic  acid.  The  authors
concluded that perhaps a different transport pathway, along with the lipoidal pathway,
existed for salicylic acid. Similarly when the absorption of benzoic acid was studied at
PH 7.19 (99.9 % of the drug existed in ionized form) it was found that >10 % of drug
was absorbed indicating that the ionized species also permeates through nasal mucosa.
Based on all of these observations, the authors discounted partition coefficients as a
major factor governing nasal absorption and supported that other transport pathways
for hydrophilic drugs might be of importance.
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 Factors Related to Formulation 9,17
Drug concentration, dose and dose volume
Drug concentration,  dose and dose volume of administration are three interrelated
parameters that impact the performance of the nasal delivery system. Nasal absorption
of  L-Tyrosine  was  shown  to  increase  with  drug  concentration  in  nasal  perfusion
experiments.  However,  in  another  study,  aminopyrine  was  found  to  absorb  at  a
constant rate as a function of concentration. 
Several  studies  have  reported  the  effect  of  drug  ‘dose’  on  nasal  absorption,
e.g.  calcitonin,  GnRH  agonist,  desmopressin,  secretin.  In  general,  higher  nasal
absorption or therapeutic effect was observed with increasing dose. It is important to
note  how the  dose  is  varied.  If  the  drug  is  increasing  by  increasing  formulation
volume, there may be a limit as to what extent nasal absorption can be increased. The
nostrils can retain only a limited volume, beyond which a formulation will drain out
of the nasal cavity. The ideal dose volume range is 0.05-0.15 ml with an upper limit
of  0.20 ml.
Physical form of formulation:
Nasal drug absorption depends on the physical form of the formulation. The important
parameter  in formulation development  is viscosity of the formulation. Generally a
more viscous  formulation will  provide  less  efficient  systemic  nasal  drug delivery.
Harris et al. studied the nasal delivery of desmopressin and reported that although the
addition of the viscous agents to nasal formulations may produced a somewhat more
sustained effect. It would seem logical that more viscous formulations e.g. gels should
be more appropriate for locally acting drugs. One may also consider developing gel
type formulations for those drugs, which cause unpleasant taste in the mouth via a
nasal drip of solution or spray formulations. Nasal  drip would be minimized from
viscous formulations. 
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Formulation pH:
The  pH  of  the  formulation  as  well  as  that  of  nasal  surface,  can  affect  a  drug’s
permeation. The pH of the nasal formulation is important for the following reasons:
• To avoid irritation of the nasal mucosa.
• To allow the drug to be available in unionized form for absorption.
• To prevent the growth of pathogenic bacteria in the nasal passage.
• To maintain functionality of excipients such as preservatives and
• To sustain normal physiological ciliary movement.
Lysozymes are found in nasal secretions, which is responsible for destroying certain
bacteria at acidic pH. Under alkaline conditions, lysozyme is inactivated and the nasal
tissue  is  susceptible  to  microbial  infection.  It  is  therefore  advisable  to  keep  the
formulation at a pH of 4.5 to 6.5 keeping in mind the physicochemical properties of
the drug as drugs are absorbed in the unionized form and also to avoid nasal irritation.
Buffer capacity:
Nasal formulations are generally administered in small volumes ranging from 25 to
200 µl with 100 µl being the most common dose volume. Hence, nasal secretions may
alter the pH of the administered dose. This can affect the concentration of un-ionized
drug available for absorption. Therefore, an adequate formulation buffer capacity may
be required to maintain the pH in-situ.
Osmolarity:
Drug absorption  can  be  affected  by tonicity  of  the formulation.  Shrinkage  of  the
epithelial cells has been observed in the presence of hypertonic solutions. Hypertonic
saline solutions also inhibit or cease ciliary activity. Low pH has a similar effect as
that of hypertonic solutions. Generally an isotonic formulation is preferred.
Gelling / viscofying agents or gel forming carriers:
Some  formulations  need  to  be  gelled  or  made  more  viscous  to  increase  nasal
residence  time.  According to  a  study by Pennington  et  al. increasing the solution
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viscosity  may  provide  a  means  of  prolonging  the  therapeutic  effect  of  nasal
preparations. Suzuki et al. showed that a drug carrier such as hydroxypropyl cellulose
was effective for improving the absorption of low molecular weight drugs but did not
produce the same effect for high molecular weight peptides. Use of a combination of
carriers is often recommended from a safety (nasal irritancy) point of view.
Solubilizers:
Aqueous solubility of a drug is always a limitation for nasal drug delivery in solution.
Conventional  solvents  or  co-solvents  such  as  glycols,  small  quantities  of  alcohol,
Transcutol,  (diethylene  glycol  monoethyl  ether),  medium  chain  glycerides  and
Labrasol  (saturated  polyglycolyzed  C8-C10 glycerides)  can  be  used  to  enhance  the
solubility of drugs. Other options include the use of surfactants or cyclodextrins such
as  HP-β-Cyclodextrins  that  serve  as  a  biocompatible  solubilizer  and  stabilizer  in
combination with lipophilic absorption enhancers. In such cases, their impact on nasal
irritancy should be considered.
Preservatives: 
Most  nasal  formulations  are  aqueous  based  and  need  preservatives  to  prevent
microbial growth. Parabens, benzalkonium chloride, phenyl ethyl alcohol, EDTA and
benzoyl alcohol are some of the commonly used preservatives in nasal formulations.
Preservatives are based in small quantities and are not likely to affect drug absorption.
Antioxidants:
Depending upon the stability profile of a given drug in the formulation chosen, it may
be  necessary  to  use  antioxidants  to  prevent  drug  degradation.  Commonly  used
antioxidants are sodium metabisulfite, sodium bisulfite, butylated hydroxytoluene and
to copherol. Usually, antioxidants are used in small quantities and they may not affect
drug  absorption  or  cause  any  nasal  irritation.  Chemical/physical  interactions  of
antioxidants and preservatives with drugs, excipients, manufacturing equipment and
packaging components should be considered as a part of formulation development
program.
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Humectants:
Many allergic and chronic  diseases are often connected with crusts and drying of
mucous  membranes.  Certain  preservatives/antioxidants  among the other  excipients
are  also likely to  cause  nasal  irritation especially  when used in  higher  quantities.
Adequate  intranasal  moisture  is  essential  for  preventing  dehydration.  Therefore,
humectants can be added especially in gel-based nasal products. Humectants avoid
nasal irritation and are not likely to affect drug absorption. Some common humectants
used include glycerin, sorbitol and mannitol.
Absorption Enhancers 1,22
When  it  becomes  difficult  for  a  nasal  product  to  achieve  its  required  absorption
profile, the use of absorption enhancers is recommended. The selection of absorption
enhancers is based upon their acceptability by regulatory agencies and their impact on
the  physiological  functioning  of  the  nose.  Absorption  enhancers  may be  required
when  a  drug  exhibits  poor  membrane  permeability,  large  molecular  size,  lack  of
lipophilicity and enzymatic degradation by aminopeptidases. Once a suitable enhancer
is  identified,  its  optimal  concentration  should  be  experimentally  determined.
Generally higher concentrations of enhancers are likely to result in nasal irritation and
damage to the nasal mucosa. On the other hand, lower enhancer concentrations would
generally provide lower or no improvement of absorption. The various compounds
investigated as enhancers in nasal drug delivery research are mentioned in Table 1.
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Table 1 : Various compounds investigated as enhancers in nasal drug 
delivery research
Surfactants
Sodium dodecyl sulfate (SDS)
Polyoxyethylene-9-lauryl ether
Phosphatidylcholines
Complexing and 
Chelating agents
Ethylene diamine tetraacetic acid(EDTA)
Cyclodextrins and 
derivatives
α-, β-, γ-cyclodextrin
DMβ-, HPβ-cyclodextrin
Bile saltsSodium 
Tauradihydrofusida
te (STDHF)
Fusidic acid 
derivatives
Sodium taurocholate
Sodium glycocholate
Dry microspheres
Degradable starch microsphere
Dextran microspheres
 Ideal Characteristics of Absorption Enhancers
The following characteristics should be considered in choosing absorption enhancers:
• The enhancer should be pharmacologically inert at concentrations used.
• It should be nonirritating, nontoxic and nonallergic.
• If the enhancer has any effect on the nasal mucosa, it should be completely 
reversible.
• The enhancer should be a potent absorption promoter therefore requiring only 
small amounts to be used.
• It should be compatible with the drug and formulation adjuvants
• It should be able to remain in contact with the nasal mucosa long enough to 
achieve a maximal effect
• The enhancer should not have any offensive odor or taste
• It should be relatively inexpensive and readily available.
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 Mechanism of Nasal Drug Absorption Enhancers:
The  enhancers  evaluated  to  date  appear  to  act  by  a  wide  range  of  mechanisms,
including  perturbation  of  lipid  membranes,  facilitation  of  leakage  of  lipids  and
proteins from the membranes, tight junction regulation, and chelation of Ca2+ ions in
the cell membranes.
Precise  mechanisms  of  enhancer  effect  are  not  known.  However,  it  is  generally
believed  that  enhancers  may show their  actions  via  one  or  both  of  the  following
mechanisms:
Physicochemical effects:
Some enhancers can alter the physicochemical properties of a drug in the formulation.
This can happen by altering the drug solubility, drug partition coefficient, or by weak
ionic interactions with the drug. This mechanism of drug absorption enhancement is
desirable because it can be effective with the lowest potential of toxicity.
Membrane effects:
Many enhancers show their effects by affecting the nasal mucosal surface. It    should
be  emphasized  that  these  effects  are  not  necessarily  harmful.  In  most  cases  the
enhancer’s  effects  are  transient  with  no lasting or pathological  consequences.  The
final decision should take into consideration the benefit to risk ratio.
Generally, the absorption enhancers act via one of the following mechanism:
• Inhibit enzyme activity;
• Reduce mucus viscosity or elasticity;
• Decrease mucociliary clearance;
• Open tight junctions; and
• Solubilize or stabilize the drug.
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 Nasal Formulations 6,23,24,25,26,27,28,29,30
Several new preparations mentioned below have been developed for nasal route not
only to prolong the contact time of the vehicle on the nasal mucosal surface but also
to slow down the drug clearance unlike nasal drops 
 Suspension9
 Powders32
 Emulsions and ointments33
 Microsphere28,34,35
 Liposomse and Proliposomes36,37
 Mucoadhesive drug delivery system38,39,40
Mucoadhesive Drug Delivery System 38,39,40
A common way of increasing residence time is by adding bioadhesive polymers to the
nasal  solutions in  order  to  increase  the viscosity and thereby decrease  the rate  of
drainage.  Mucoadhesive  drug  delivery  systems  that  utilized  the  property  of
bioadhesion of certain polymers, which becomes adhesive on hydration and hence can
used for targeting a drug to a particular region of the body for extended periods of
time.
In general it is assumed that the polymers and microspheres interact with mucus and
the tissue surface with a resulting increase in contact  time.  Many commonly used
bioadhesive  polymers  are  anionic  or  nonionic  compounds  with  active  hydrophilic
functional groups, which can form hydrogen bond along the polymer chain and with
mucus.
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 Bioadhesion and Mucoadhesion:
The idea of using bioadhesive polymers to prolong the contact time in the mucosal
routes  of  drug delivery was introduced  in  the  early  1980s and,  since  then,  it  has
attracted considerable attention from pharmaceutical scientists. The potential of the
drug delivery system to localize a drug at the site of absorption for an extended period
of time and to promote intimate contact between the formulation and the underlying
absorbing tissue has great appeal to both local and systemic effects. Good considered
Bioadhesion  to  be the phenomenon in  which two materials,  at  least  one being of
biological nature, are held together for extended periods of time by interfacial forces.
Bioadhesion has been defined by Longer and Robinson as the attachment of synthetic
or biological macromolecules to a biological tissue. If the adhesive attachment is to a
mucous coat, the phenomenon is referred to as Mucoadhesion.
 Mechanism of Mucoadhesion
For Bioadhesion to occur,  a succession of phenomena, whose role depends on the
nature  of  the  bioadhesive  is  required.  Following  few  steps  are  involved  in
Mucoadhesion process.
1. Spreading, wetting and swelling of the dosage form at the mucous surface,
initiates intimate contact between the polymer and the mucous layer.
2. Interdiffusion  and  interpenetration  take  place  between  the  chains  of  the
mucoadhesive polymer and the mucous gel network, creating a greater area of
contact.
3. Entanglement and secondary chemical bonds are formed between the polymer
chains and mucin molecules.
It  can be noted that, for polymer gels that are already in equilibrium swelling,  the
wetting and swelling step is unlikely to be involved.
The component of the mucus involved in interactions is the mucin molecules. These
are glycoproteins of high molecular weight (in the range of 1-50.106  Dalton) present
in  the  concentration  of  0.5-5  %,  which  are  also  responsible  for  the  viscoelastic
properties of the mucus. The mucin is negatively charged at physiological PH because
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of  sialic  acid  residues  in  the  oligosaccharide  units.  On  a  molecular  level,
mucoadhesion can be explained based on molecular interactions. Hydrogen bonds are
often considered to be the most important  of the types  of the secondary chemical
bonds that can be formed in the mucoadhesion process.  Other types of bonds that
might be involved include ionic bonds and Vander Waals interactions.          
 Factors affecting Mucoadhesion
The mucoadhesive power of a polymer is affected by the nature of the polymer and
also  by  the  nature  of  the  surrounding  media.  The  factors  influencing  the
mucoadhesion are as follows,
I. Polymer related factors
• Molecular weight
• Concentration of active polymer
• Flexibility of polymer chains
• Special confirmation
• Swelling
II. Environment related factors
• pH of the polymer-substrate interface
• Applied strength
• Initial contact time
III. Physiological factors
• Mucin turnover
• Disease state
 Methods for measuring mucoadhesion
Several  test  methods  have  been  reported  in  literature  for  studying  mucoadhesion.
These  tests  are  important  during  the  design  and  development  of  a  bioadhesive
controlled  release  system  as  they  ensure  compatibility,  physical  and  mechanical
stability, surface analysis and bioadhesive bond strength. The methods reported are as
follows.
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 I) In- vitro/Ex vivo methods
• Methods based on measurement of tensile strength.
• Methods based on measurement of strain strength.
II) Other in- vitro methods:
• Adhesion weight method
• Fluorescent probe method
• Flow channel method
• Mechanical spectroscopic method
• Falling liquid film method
• Colloidal gold staining method
• Viscometric method
• Thumb test
• Adhesion number
• Electrical conductance
III) In- vivo methods:
• Use of radio isotope
• Use of gamma scintigraphy.
1.11.5 Advantages of mucoadhesive drug delivery systems:
Mucoadhesive dosage forms have distinct advantages when compared to conventional
dosage forms.
1. These dosage forms are readily localized in the region applied to improve and
enhance the bioavailability of drugs.
2. The  dosage  forms  facilitate  intimate  contact  of  the  formulation  with  the
underlying  absorption  surface.  This  allows  modification  of  the  tissue
permeability for absorption of macromolecules such as peptides and proteins.
Inclusion  of  penetration  enhancers  such  as  sodium  glycholate,  sodium
taurocholate  and  protease  inhibitors  in  the  mucoadhesive  dosage  forms
resulted in the better absorption of the peptides and proteins.
3. Mucoadhesive dosage forms also prolong residence time of the dosage form at
the site of application and absorption to permit once or twice a day dosing.
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Mucoadhesive polymers
Bioadhesive polymers have been used extensively in nasal drug delivery systems to
provide dosage forms retention. Bioadhesive polymers are defined as polymers that
can adhere  to  a  biological  substrate.  The term mucoadhesion is  applied when the
substrate is mucosal tissue. Diverse classes of polymers have been investigated for
their potential use as mucoadhesive.
Mucoadhesive polymers are water soluble and water insoluble polymers which are
swellable  networks  joint  by  cross  linking  agents.  The  polymers  should  possess
optimal  polarity  to  make  sure  it  is  sufficiently  wetted  by the  mucus  and  optimal
fluidity that permits the mutual adsorption and interpenetration of polymer and mucus
to take place. Ideal polymers for mucoadhesive drug delivery system should have the
following characteristics;
• The  polymers  and  its  degradation  products  should  be  nontoxic  and
nonabsorbable from the gastrointestinal tract.
• It should be a nonirritant to the mucous membranes.
• It should preferably form a strong noncovalent bond with the mucin epithelial
cell surface.
• It  should  adhere  quickly  to  moist  tissue  and  should  possess  some  site
specificity.
• It should allow easy incorporation of the drug and offer no hinderance to its
release.
• The polymer must not decompose on storage or during shelf life of the dosage
form.
• The cost of the polymer should be not to high, so that prepared dosage form
remains competitive.
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Table 2 : Mucoadhesive polymers used in Nasal drug Delivery 
The interaction between the mucus and bioadhesive polymers is a result of physical
entanglement  and  secondary  bonding  mainly  hydrogen  bonding  and  vander  walls
attraction. These forces  are related to the chemical  structure of the polymers.  The
functional  groups  available  on  the  surface  of  the  polymer  conformation  favoring
bioadhesion  include  hydroxyl,  carboxyl,  amines  and  amides.  The  bioadhesive
polymers must have a critical molecular weight and an adequate length to allow chain
interpenetration.  Anionic polymers  are usually preferred due to negatively charged
mucin at physiological pH.
                                                                                                                             
                                                                                                                                    
 
Polymers Bioadhesive property
Carboxy methyl cellulose + + +
Carbopol 934 + + +
Polycarbophil + + +
Tragacanth + + +
Poly(acrylic acid/divinyl benzene) + + +
Sodium alginate + + +
Hydroxy ethyl cellulose + + +
Gum karaya ++
Thermally modified starch ++
Pectin ++
Polyvinyl pyrrolidene +
Acacia +
Polyethylene glycol +
Psyllium +
Amberlite-200 resin +
Hydroxypropyl cellulose +
Chitosan +
31
 Phase Transition System 41,42
There are polymeric solutions prepared from water soluble polymers that are able to
form gels after application to delivery sites that is they gels once in position.
Preferred excipients for liquid compositions is one that allows the composition to be
administer as a mobile liquid and in the nasal cavity will cause the liquid composition
to gel,  thereby  providing  a  bioadhesive  effect  which  acts  to  hold the  drug  at  the
absorptive  surface  for  an  extended  period  of  time.  A  vitamin  B12 gel  has  been
recently developed as a prescription product.
To solve the problems of conventional nasal drops, it would be desirable to developed
a phase transition system which,
• Forms a gel at physiological condition
• Has suitable gel  strength,  not  to leak out from the nasal  cavity after  nasal
administration.
• Has a suitable bioadhesive force so as to increase the residence time.
 Advantages of phase transition system:
The main advantage of using phase transition system is that,
• They are fluid like prior to contact with the mucosa and thus can be readily
administered as a drop or by a spray device.
• The formulation adopts semisolid properties when gelling is induced by some
physiological stimulus at the site of administration, which increases residence
time due to mucoadhesive property.
• Bioavailability increase due to increase in residence time.
• Reduced the dosing frequency
These systems consist of polymers that exhibit sol to gel phase transitions due to a
change in specific physiological parameter (pH, temperature) in environment of the
nasal cavity. Depending on the method employed to cause sol to gel phase transition
in nasal cavity, the following three types of systems are recognized.
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• pH  triggered  systems-  Cellulose  acetate  hydrogen  phthalate,  carbopol,
chitosan.
• Ion activated systems- Gelrite, alginates.
• Temperature dependent systems- Pluronic and tetronics
Such  systems  have  gain  significant  interest  among  the  formulators  within  the
pharmaceutical  field  as drug delivery vehicle and have been evaluated  for  several
administration  routes  as  nasal,  ophthalmic,  oral,  dermal,  rectal,  vaginal,  and
parenteral.
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CH. II.  LITERATURE REVIEW.  
• Illum, et al., studied intranasal delivery of morphine, the article describes the
development of novel nasal morphine formulations based on chitosan showing
5 to 6 fold increase in bioavailability over simple morphine solution.19
• Aikawa,  K., et  al.,  developed  nasal  formulations  of  polyvinylacetal
diethylaminoacetate  (AEA)  and  the  effect  of  AEA  concentration  on  drug
release was evaluated in in-vitro and in vivo experiments. Hydrogel formation
on mucous membrane was also visually confirmed in rat nasal cavity.  Such
gels would swell significantly when in contact with the mucosa (the pH of the
mucosa is almost 7.0) and the release of the drug in a continuous fashion while
adhering to the mucosa. From the results they concluded that AEA preparations
which  facilitate  instillation  into  the  nose  but  which  form  hydrogel  on  the
mucous membrane are potentially useful for controlled release nasal delivery
system.25
• Mao,  S.,  et  al., studied  melatonin  starch  microspheres  for  intranasal
administration, which could be capable of providing a fast onset and controlled
release behavior. The deposion and subsequent clearance of the drug from the
nose was investigated by gamma scintigraphy and absolute bioavailability was
calculated.  In vitro release experiments showed that  melatonin was released
from the microspheres in a sustained manner. T1/2 of the pure melatonin was 5.6
min.,  whereas  a  value  of  12.3  min.  was  observed  for  melatonin  starch
microspheres. Nasal clearance studies showed that > 80% of the radioactivity
from the starch microspheres was present in the nasal mucosa 2 hours after
administration compared  to only 30 % radioactivity  from the solution.  The
absolute bioavailability of the melatonin starch microspheres after intranasal
administration was 84.07 %.29
• Nagai,  T.,  et al., studied powder dosage of insulin for nasal administration.
The results showed that addition of bioadhesive polymers in a powder nasal
dosage form of insulin resulted in an increase in bioavailability as compared to
an insulin solution.31
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• Illum  et  al. in  their  in  vivo study  using  formulations  using  bioadhesive
microspheres for nasal administration reported that, the intranasal clearances of
three microsphere systems, albumin, starch, and DEAE-dextran microspheres
were much slower than the intranasal  clearances of the control solution and
powders. Half time for the clearance of the microsphere systems were 3 hours
or  longer  while  the  half  times  for  the  clearance  of  the  control  solution  or
powders were approximately 15 minutes.35
• Chenite, A. et al., studied novel injectable neutral solutions of chitosan. This
study reported for the first time the use of polymer/polyol salt aqueous solution
as gelling systems, suggesting the discovery of a prototype for a new family of
thermally gelling, highly compatible with biological components.43
• Shaoyun, Yu. et al., studied nasal insulin delivery in the chitosan solution. The
investigation  described  the  effect  of  chitosan  concentration  and  absorption
enhancers  in  the  chitosan  solutions  on  nasal  insulin  delivery  showing  a
significant  effect  on  the  insulin  nasal  delivery.  This  study  showed  that  the
combination of chitosan and HP – β cyclodextrin is most effective in enhancing
the absorption of  insulin in nasal delivery system compared to the  formulation
containing 1 % chitosan alone or 5 % HP – β cyclodextrin alone.44
• Chenite,  A.  et  al.,  studied  rheological  characterization  of  thermogelling
chitosan / glycerophosphate solution.The paper discusses about the temperature
triggered  hydrogel  formation  by  chitosan  coupled  with  sodium  beta
glycerophosphate. 45 
• Hussain,  et al., studied nasal bioavailability of propranolol and its salt from
different formulations in rats, dogs, and human and concluded that in all three
species,  nasal absorption was as effective as intravenous injection and much
superior to oral absorption. 46
• Hussain,  A.  et  al., in  their  study  of  nasal  absorption  of  propranolol  from
different  dosage  forms  in  rats  and  dogs  demonstrated  the  utility  of
methylcellulose with the report that the addition of 3 % methylcellulose to a
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nasal  solution  of  propranolol  produced  a  sustained  blood  level  over  an
extended time period. 47
• Anne,  P.,  et  al., formulated  a  injectable  poloxamer  based  gel  of  lidocaine
hydrochloride and ibuprofen Na and studied the effect of drug release from the
poloxamer based gel and poloxamer gel with different additives like HPMC,
sodium  carboxymethylcellulose,  and  dextran.  The  study  was  carried  out
in vitro using porcine dura mater membrane. The result showed that cellulose
additives  significantly  prolonged  ibuprofen  release,  whereas  other  additives
were found to have slight release increasing effect on lidocaine as compared
with  poloxamer  gel.  From  the  result  it  was  concluded  that  the  structural
differences of the gel, more than macroviscosity seems to regulate the release
of  drugs.  The  compact  gel  depot  acted  as  the  rate  limiting  step,  and
significantly  prolonged  the  dural  effects  of  the  gels  demonstrated  the
possibility for interactions between dural membrane and the gel.48
• Paavola,  A.,  et  al., studied  controlled  release  injectable  liposomal  gel  of
ibuprofen  for  epidural  analgesia  and  investigated  the  possibility  of  using
liposomal systems to control  the release and dural  permeation of ibuprofen.
The  liposomal  gel  consisted  of  poloxamer  407  and  the  liposomal  solution.
Ibuprofen  release  in  phosphate  buffer,  pH  7.4  at  370C from  the  liposomal
solution and  the  liposomal  gel  were  prolonged  significantly  compared  with
their  respective  solution  and  gel  controls.  The  liposomal  gel  controlled
ibuprofen  release  and  dural  permeation  in  vitro and  showed  a  permeation
pattern  favorable  for  maintaining  constant  drug  levels.  The  liposomal
poloxamer  gel  represents  a  new formulation approach  to  increase  the  local
epidural  availability  of  ibuprofen.  It  appeared  to  be  a  promising  injectable
controlled release drug delivery system.49
• Choi, et al., studied in- situ gelling and mucoadhesive suppository to solve the
problems  of  conventional  solid  suppositories,  which  forms  gel  at  body
temperature, has a suitable gel strength does not leak out from the anus after
administration and has a suitable bioadhesive force so as not to reached the end
of  the  colon.  From  the  results  of  these  studies,  it  was  suggested  that  the
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mixtures of P407/P188 (15/15-15/20) are the optimal systems, which had the
gelation  temperature  suitable  for  acetaminophen  liquid  suppository.
Furthermore, they suggested that less than 1.0 % of carbopol or polycarbophil
must be added to prevent the leakage of the suppositories from the anus and
retain the gelled suppositories in the rectum. This system might be applicable
for the development of in situ gelling and mucoadhesive liquid suppository for
humans as a more convenient and effective rectal dosage form.50
• Kim, C. K., et al., developed in-situ gelling and mucoadhesive acetaminophen
liquid suppository using poloxamers and sodium alginate to improve patient’s
compliance  of  conventional  acetaminophen  suppository.  Pharmacokinetic
study from liquid and conventional solid suppositories in human subjects was
carried  out.  The  results  showed that  acetaminophen liquid suppository with
optimal gelation temperature, gel strength and bioadhesive force had a similar
release pattern to conventional suppository,  which was easy to administer to
the anus and showed faster  absorption of acetaminophen in human subjects
than  conventional  suppository,  was  more  comfortable  for  the  patients  and
therefore was thought to be a favorable anti-pyretic and analgesic dosage form
for infants and children.51
• Elhady,  S.  S.,  et  al., developed  in  situ gelling  and  mucoadhesive  rectal
solution of Mebeverine hydrochloride (MbHCL), which suffers from extensive
first  pass  effect,  to  improve  its  bioavailability  and  possibly  restrict  its
absorption to only the lower rectum. Mixtures of poloxamer 407 and 188 were
used to confer the temperature sensitive gelation property. To modulate the gel
strength  and  mucoadhesive  force  of  MbHCL  poloxamer  rectal  solution,
mucoadhesive  polymers  such  as  HPMC,  HEC,  methylcellulose  and
polyvinylpyrrolidone K15M were  investigated.  The result  showed that,  these
polymers reinforced the gel strength and mucoadhesive force of the prepared
solutions.  Increasing  the  concentration  of  cellulosic  bioadhesive  polymers
retarded the release of MbHCL and it was possible to sustain the drug effect
over a period of period of 8 hours.52
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• Morimoto,  et  al., showed  the  nasal  absorption  of  nifedipine  from  gel
preparations in rats. They used PEG 400, aqueous carbopol gel in investigating
high bioavailability and prolong action of the drug.  Nasal  administration of
nifedipine in PEG resulted in rapid absorption and high Cmax, however, the
elimination  of  nifedipine  from  plasma  was  very  rapid.  Nifedipine  plasma
concentration after its nasal administration in aqueous carbopol gel formulation
was very low. On the other hand, carbopol-PEG gel containing 50% PEG 400
showed a relatively high nifedipine concentration in the rat blood and prolongs
its action.53
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CH. III .
PLAN OF WORK
• Procurement and characterization of drug sample.
• Interaction studies between drug and polymers.
• Formulation of stable phase transition system.
• Evaluation of phase transition system for
 Viscosity 
 Mucoadhesion.
 In-vitro release.
 In-vitro permeation studies to evaluate the effect of penetration              
      enhancers in improving permeability through porcine nasal mucosa.
 Drug content
• Stability studies.  
  
         
 
                                                                                                                             
                                                                                                                                    
 
39
CH. IV.  Materials and Methods.
4.1 Materials 
Sr. No. Materials Supplier
1.   Drug Cipla Lab. Mumbai.
2.    Chitosan HCl Mahtani  Chitosan  Pvt.
Ltd. Veraval
3.     Hydroxypropyl Cipla Lab. Mumbai.
Beta Cyclodextrin
    4. Benzalkolium Chloride Red Cross Formulation, Aurangabad.
    5. Sodium Beta Red Cross Formulation, Aurangabad.
glycerophosphate
   6. Sodium Chloride --
   7. Distilled Water --
Note  :  -   As  the  work  is  carried  out  at  commercial  organization  (  Red  Cross
Formulation, Aurangabad ).  So the name of pure drug remain confidential and is
denoted as “ Drug ”.
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4.1.1 Instruments 
Double Beam UV Spectrophotometer.
Mode No-UV 2401(PC), S.220V.
2. Electronic Weighing Balance 
Model No. AW-220.
Shimadzu Corporation, Japan.
3. Electronic Weighing Balance. 
Model No. BX 6205.
Shimadzu Asia Pasific Pvt. Ltd.Singapur.
4. pH Meter
Model No. (Systronics 361)
5. Brookfeild Viscometer. 
Model RV DVG-230
Brookfeild Engg. Lab., Inc., Stoughton.
6. Peristaltic Pump
Model PP201V
Electrolab, Mumbai.
7. Fourier Transmittance Infrared Spectrophotometer.
Model 84005, Shimadzu Asia Pasific Pvt. Ltd.Singapur.
8. Brookfield CAP Viscometers
Models CAP 2000
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CH.V
Drug Profile 54,55,57,58,59
Category : Beta-Adrenoceptor blocker.
Description            : White odorless powder
Solubility               : Sparingly soluble in water, soluble in ethanol, slightly soluble 
  in dichloromethane  practically insoluble in ether.
pKa                          : 9.6(240 C)
Partition coefficient : Log P(octanol/water),0.23
pH                            :  9.7 (in 1% solution )
Half life                   :  5-8 hours.
Oral Bioavailability :  about 50 %
Melting point              :150-1520c
Pharmacopial Status : Official in USP, IP, USP 
Pharmacological action:
Drug  is  a  ß1-selective  adrenergic  antagonist  that  is  devoid  of  intrinsic
sympathomimetic activity and membrane stabilizing property.
Pharmacokinetics:
Absorption:
Drug  is  incompletely  absorbed  from  the  gastrointestinal  tract;  following  oral
administration about 50 % is absorbed. Peak plasma concentrations of upto 2 µg/ml
are reached in 2-4 hours &  has low lipid solubility. 
Distribution:
Drug is widely distributed; it crosses the placenta and is excreted in breast milk. Only
small amounts are reported to cross the blood brain barriers, plasma protein binding is
minimal. Its  plasma protein binding is less than 5 %. Its  volume of distribution is
about 0.5 to 1.5 L/kg
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Metabolism: 
Only a small part of Drug is metabolized, about 10 % of a dose &  is characterized by
low hepatic clearance.
Elimination:
Mostly  of  the  drug  is  eliminated,  in  its  unchanged  form,  by  several  routes,  but
prevailing via the kidney.
Therapeutic uses:
Drug is a cardio selective ß-blocker. It  is used in the management of hypertension,
cardiac  arrhythmias  and  myocardial  infarction.  It  is  also used in  the  treatment  of
hyperthyroidism and migraine.
Adverse effects:
Effects  on  heart: 2.5  mg  by  intravenous  induced  atrial  fibrillation  in  6  of  12
predisposed patient.
Effects  on  gastrointestinal  tract: Reports  of  sclerosing  peritonitis  and
retroperitoneal fibrosis in a patient taking drug. 
Effects on vision: visual sysmptoms without headache were reported with drug for
migraine  prophylaxis  in  a  patient  who  had  experimented  a  similar  reaction  with
nadolol. 
Effects  on  lipid  metabolism: ß-blockers  may  increase  serum-triglyceride
concentrations and there has been a report of acute pancreatitis being provoked by
severe  hypertriglyceridaemia  in  a  patient  in  whom  ß-blockers  greatly  impaired
triglyceride clearance.
Effect on the Liver: A report of reversible cholestatic hepatitis in a patient receiving
drug and hepatic dysfunction.
Interactions:
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Catecholamine-depleting drugs (ex. reserpine may have an additive effect when given
with ß-blocking agent. 
Contraindications:
It  is  contraindicated  in  sinus  bradycardia,  heart  block  greater  than  first  degree,
cardiogenic shock, and overt cardiac failure.
Dose:
Usual adult dose:
Antihypertension: in  hypertension,  drug is  given  by  mouth  in  a  dose  of
50-100 mg daily, as a single dose, although 50 mg daily is generally adequate. The
full effect is usually evident within 1 to 2 weeks.
Angina pectoris: The usual dose for angina pectoris is 50-100 mg daily by mouth,
given as single or divided doses.
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 Polymer profile
Chitosan Hydrochloride 60,61,62,63
Nonproprietary Names : Chitosan Hydrochloride,Chitosan Hydrochloridum
Synonyms : Deacetylated chitin; Deacetylchitin
Chemical name : Poly-Beta-(1,4)-2-Amino-2-deoxy-Dglucose
Empirical formula molecular weight :
Partial  deacetylation  of  chitin  results  in  the  production  of  chitosan,  which  is  a
polysaccharides  comprising copolymers  of glucosamines  and N-acetylglucosamine.
Chitosan is the term applied to deacetylated chitins in various stages of deacetylation
and  depolymerisation  and  it  is  therefore  not  easily  defined  in  terms  of  its  exact
chemical composition. A clear nomenclature with respect to the different degrees of
Ndeacetylation between chitin and chitosan has not been defined and chitosan is not
one  chemical  entity  but  varies  in  composition  depending on  the  manufacturer.  In
essence, chitosan is chitin sufficiently deacetylated to form soluble amine salts. The
degree of deacetylation necessary to obtain a soluble product must be greater than
80-85 %. Chitosan is commercially available in several types and grades that vary in
molecular weight between 10000 and 1000000,and vary in degree of deacetylation
and viscosity.
Structural formula :
Functional category:
Coating agent, disintegrant,  film forming agent,  mucoadhesive, viscosity-increasing
agent. 
Description: Chitosan occurs as odorless, white or creamy white powder or flakes.
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HCl
Solubility : Chitosan hydrochloride is soluble in water.
Solution pH:  pH of 1%w/v solution is 4.0-6.0.
Incompatibilities: Chitosan is incompatible with strong oxidizing agents.
Applications in pharmaceutical formulation or technology:
Chitosan  is  used  in  cosmetics  and  is  under  investigation  for  use  in  a  number  of
pharmaceutical  formulations.  The  suitability  and  performance  of  chitosan  as  a
component of pharmaceutical  formulations for drug delivery applications has been
investigated in numerous studies These includes controlled drug delivery application,
use  as  a  component  of  mucoadhesive  dosage  forms,  rapid  release  dosage  forms,
improved peptide delivery, colonic drug delivery systems and use for gene delivery.
Chitosan has been processed into several pharmaceutical forms including gels films,
beads, microsphere, tablets, and coating for liposomes. Further more chitosan may be
processed into drug delivery systems using several techniques including spray drying,
coacervation, direct compression and conventional granulation processes.
Using chitosan in conventional solid dosage forms:
Chitosans film forming abilities lend itself well as a coating agent for conventional
solid dosage forms such as tablets. Furthermore its gel-and matrix forming abilities
makes it useful for solid dosage forms such as granules, microparticles, etc. Sakkinen
and coworkers studied microcrystalline chitosan as a gel forming excipient for matrix
type drug granules. Crystallinity, molecular weight and degree of deacetylation were
seen to be factors that affected the  release rates from the chitosan based granules
.Combination of positively charged chitosan with negatively biomolecules,  such as
gelatin, alginic acid ,and hyaluronic acid, has been tested to yield novel matrices with
unique characteristics for controlled release of drugs.
Site specific targeting:
Tozaki and coworkers utilized chitosan capsules for colon specific  delivery totreat
ulcerative colitis.  A5-amino salicylic  acid was encapsulated into chitosan capsules
and delivered in vivo to male wistar rats after induction of colitis .it was observed that
chitosan capsules disintegrated specifically in the large intestine as compared to the
controll formulation (in absence of chitosan) which demonstrated absorption of the
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drug in small intestines, this data is a representative example of utility of chitosan for
colon specific delivery, while the mechanism of chitosan disintegration is speculative
at this point in time, the excipients has promise for site- specific delivery. 
Chitosan as permeation enhancer: 
It has been reported that chitosan, due to its cationic nature is capable of opening tight
junctions  in  a  cell  membrane.  This  property  has  led  to  a  number  of  studies  to
investigate the use of chitosan as a permeation enhancers for hydrophillioc drugs that
may otherwise have poor oral bioavailability, such as peptides, because the absorption
enhancement is caused by interaction between the cell membrane and positive charges
on the polymer,  the phenomenon is  pH and concentration dependent.  Furthermore
increasing the charge density on the polymer would lead to higher permeability this
has been studied by quaternising the amine functionality on chitosan.
Chitosan as mucoadhesive excipients:
Bioadhesivity is often used as an approach to enhance the residence time of a drug in
the gastrointestinal  tract,  thereby increasing the oral  bioavailability.  A comparison
between chitosan and other commonly used polymeric excipients indicates that the
cationic polymer has higher bioadhesivity compared to other natural polymers, such
as cellulose, xanthan gum and starch
Stability and storage condition:
Chitosan powder is a stable material at room temperature, although it is hygroscopic
after drying. Chitosan should be stored in a tightly closed container in a cool, dry
place. The Ph.Eur. 2002 specifies that chitosan should be stored at a temperature of
2-80C.
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  EXCIPIENTS
   Benzalkolium Chloride 
Synonym :- Alkyl Dimethyl Benzyl Ammonium Chloride 
Molecular Formula :-
[  C6H5CH2N(CH3)2 R] Cl.
Molecular Weight :-   360.
Description :-  It occurs as white or yellowish white amorphous powder, a thick gel
or gelatinious flakes. It is hygroscopic, soapy to touch and has mild aromatic odour
and has bitter taste. 
Functional Category :-   Antimicrobial Preservative, Antiseptic, Disinfectant 
   Solubalizing agent, Wetting agent. 
Solubility :-    Partially insoluble in ether, very soluble in acetone, ethanol, methanol
and water. 
Stability and Storage :-  It is hygroscopic and may be affected by light, air, metals.
Solutions  are  stable  over  wide  Ph  and  temperature  range  may  be  sterilized  by
autoclaving  without  loss  of  effectiveness,  solutions  may  be  stores  for  prolonged
period at room temperature.      
pH       :-      5 to 8 for 10 % w/v aq. soln.
Melting Point :-   40 0c.
Density :-   0.98 gm/cm3 at 20 0c.       
Application   :-   It  is  used  in  pharmaceutical  formulation  as  an  antimicrobial
preservative. In nasal formulation the concentration of 0.002 % to 0.02 % is used. It is
also used as preservative in cosmetics.
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   Hydroxypropyl Beta Cyclodextrin 
Synonym :-   Beta Cyclodextrin 2-hydroxypropyl ether. 
Molecular Formula :-
C22H32N2O2
Molecular Weight :-   356.50.
Description :- It is water soluble, free flowing, white odorless powder. It is produced
from  Beta  Cyclodextrin  by  hydroxylpropylation  of  hydroxyl  groups  of  the
cyclodextrin.
Functional Category:-   Suitable for molecular encapsulation of variety of sparingly
water  soluble  compounds  to  enhance  the  aqueous  solubility  of  the  encapsulated
compounds.  
Solubility :-  45 % (w/v) aq 2-hydroxypropyl-β-cyclodextrin.
Storage Temperature :-  2 to 8 0C.
Optical Activity :-  [α ] /D + 7.80, c = 0.825 in methanol(lit).
Application   :-    It  is  used  for  solubalization  and  stabilization  of  guests.  By
complexing  with  HPBCD,  the  guest  interacts  with  cavity  of  HPBCD  to  become
entrapped. The outer surface of the HPBCD is very hydrophilic  and interacts well
with water to carry the guest into the solution. Some proteins can also be solubalized
with HPBCD. 
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   Sodium Beta glycerophosphate 
Synonym :- 2- glycerophosphate Disodium Salt 5-H20
Molecular Formula  :-
      C3H17Na2O11P
Molecular Weight  :-   306.11. 
Description :- It is water soluble, free flowing, white odorless powder.
Functional Category :-   Induces hydrogel formation when placed at physiological 
temperature.
Solubility       : -  Water Soluble 0.1 gm/ml clear, colourless. 
Storage Temp :-  2 to 8 0c.
Melting Point :-  102 to 104 0c
Application  :  -   It  is use  for  the  preparation  of  temp.  triggered  phase  transition
system.  
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  Sodium Chloride 
Synonym                 :-     Common Salt, Table Salt, Sea Salt. 
Molecular Formula :-   NaCl.
Molecular Weight  :-  58.44.
Description  :- 
NaCl occurs as white crystalline powder or colourless crystals, it has saline
taste.  The  crystal  lattice  is  face-centered  cubic  structure.  It  contents  no  water  or
crystallization although below 0 0c. Salt may crystallize as dehydrate.
Functional Category:-   Isotonicity modifier for nasal and opthalmic formulation.
Solubility : -  Water Soluble
Storage :-  At room temp.
pH      :-        6.7 – 7.3  
Boiling Point :-141  0c
Applications  :-   NaCl  is  widely  used  in  variety  of  parentral  and  non  parentral
formulation. It is used as isotinicity modifier.
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CH. VI.   
 EXPERIMENTAL  INVESTIGATION. 
 Preliminary Study 
 Characterization of Drug.55,57,59
Drug was characterized according to I.P. and USP.
Description:
• Nature : Amorphous powder
• Color  : White
• Odor : Odorless
• Solubility : Sparingly soluble in water.
• pH : 9.7, determined in a1% w/v solution
• Melting point :       150-152 0c.    
• Identification:
• UV absorption spectroscopy        
Drug solution of 100 µg/ml in phosphate buffer saline pH 7.4 was scanned in the 
range of 200- 400 nm.
The λmax
 
for drug was found to be 274 nm
 
as shown in Figure 8.
 Scanning of λmax of drug by UV spectrophotometry:
Scanning was done in  phosphate  buffer  saline (PBS) pH 7.4 (disodium hydrogen
phosphate 2.38 g, potassium dihydrogen phosphate 0.19 g and sodium chloride 8.0 g
for  1000 ml).  A solution of 100 µg/ml  drug was prepared  and UV spectrum was
recorded in the range of 200-400 nm.
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 Characterization of Chitosan Hydrochloride 
pH determination45,63 
: 1 % w/v solution of chitosan hydrochloride solution in water was made and pH of
solution was measured using pH meter. 
Observation :  pH was found to be 5.4(reported 4.0- 6.0). 
Gelation study : 
1 % w/v  of chitosan HCl was made and neutralized with 1 molar NaOH. 
Observation : Above pH 6.2 chitosan HCl forms hydrated gel like structure .
 Drug Polymer Interaction Study
Drug polymer interaction studies were carried out by two methods
1) UV Spectrophotometry
2) FTIR Spectroscopy
 UV spectrophotometry 42
In order to see drug polymer interaction, 100 µg/ml of pure drug solution, chitosan
hydrochloride  solution,  chitosan  hydrochloride  solution  containing  drug,  were
scanned for UV absorption between 200 to 400 nm. UV scans of polymeric solutions
containing drug were compared with those of pure drug solution. UV spectra shown
in  Figure11
 FTIR Spectroscopy 42,56,57,65
To see  drug  polymer  interaction  FTIR  studies  were  carried  out.  Pure  drug,  pure
chitosan  hydrochloride,  physical  mixture  of  drug  and  chitosan  hydrochloride  was
analyzed using KBr disk method. FTIR spectra are shown in Figure 12.
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 Standard curve of drug : Standard curve of a drug was prepared in phosphate buffer
saline pH 7.4 Drug was dissolved in phosphate buffer saline pH 7.4 to get the stock of
concentration 1000 µg/ml. From this stock solution serial dilution was done to get
drug concentration of 10 to 100 µg/ml. The absorbance of the solutions was measured
against  PBS  7.4  as  a  blank  at  274  nm,  using  double  beam  UV-  visible
spectrophotometer. The graph of absorbance v/s concentration is shown in Figure 13.
The absorbance’s of drug are shown in Table 3.  The standard calibration curve is 
depicted in Figure 13.
 Dose Calculation54,5
5
 
Oral dose of  Drug is 50-100 mg daily in one or two doses. 
I. V. injection in a dose of 2.5 mg at a rate of 1 mg / min is given with a total dose
10 mg.
Oral bioavailability is only 50 % due to low lipid solubility. 
So 20 mg of dose was fixed for nasal administration because nasal administration is
reported to provide bioavailability comparable to i. v. dose.
Nasal cavity has a capacity of 4 – 5 drops/ nostril i.e. 160-200 µl respectively.
5 % Drug in formulation contain 50 mg/ ml 
Therefore 10 mg / 200 µl or 5 drops in one nostril and 20 mg in both nostril.
 Solubility of Drug.55,66,67
Drug is sparingly soluble in water with the solubility of about 16 mg/ml. For nasal
drug delivery the drug must have higher solubility, so that the therapeutic dose can be
incorporated in the maximum volume of 200 µl in each nostril.  
So HP β cyclodextrin was used to enhance the solubility of drug in water. Various
molar ratios of drug to HP β cyclodextrin were made and the solubility was checked.
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Not  more  than  5  %  w/w  of  HP  β  cyclodextrin  is  recommended  for  nasal
administration, therefore molar ratio 1:0.19 was selected considering safety and this
concentration is sufficient to give the solubility sufficient enough to incorporate the
dose (20 mg) in 0.4 ml for both nostril of nasal solution.
Table 4 : Solubility of drug in water with different ratios of HP β CD
Molar ratio of 
Drug: HP β CD
Solubility of Drug
(mg/ml)
1:0 16
1:0.19 60
1:0.50 95
1:1 140
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 Formulation of Phase Transition System .
The formulation 0
● A separate solution of drug with hydroxy propyl β-cyclodextrin was prepared.
● The formulation 0 was prepared without adding chitosan hydrochloride and sodium
β - glycerophosphate.
●Sodium chloride was added to maintain isotonicity. 
●Finally  benzalkonium  chloride  was  added  and  the  volume  was  make  up  with
distilled water. 
●The final pH of the formulation was adjusted to 6.8.
●Each ingredient was separately sterilised by autoclaving at 1210C and 15 Psig for 20
minutes and added aseptically in laminar air flow work station. 
Table 5 : Composition of drug phase transition systems 
Sr no ingredients Quantity taken
1 Drug (g) 5
2 HP-β-CD (g) 5
3 Sodium Chloride (g) 0.5
4 Benzalkonium Chloride (ml) 0.02
5 Distilled Water (ml) Upto 100
Formulation 1
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● 
The formulation 1 using 1 % chitosan hydrochloride as mentioned in the table was
prepared by dissolving the chitosan hydrochloride in the distilled water and cooling to
~40 C. 
●  The  pH was  lowered  by  1M HCl  To this  solution  sodium β-glycerophosphate
solution was added drop by drop with continuous stirring. 
●  To  the  chitosan  hydrochloride/glycerophosphate  solution  a  separately  prepared
solution of drug with hydroxy propyl β-cyclodextrin was added.  . 
●  Sodium chloride was added to maintain isotonicity.
●  Finally  benzalkonium  chloride  was  added  and  the  volume  was  make  up  with
distilled water. 
● The final pH of the formulation was adjusted to 6.8. 
● Each ingredient was separately sterilised by autoclaving at 1210C and 15 Psig for 20
minutes and added aseptically in laminar air flow work station. 
Table 6 : Composition of drug phase transition systems using Chitosan
hydrochloride
Sr no ingredients Quantity taken
1 Drug (g) 5
2 HP-β-CD (g) 5
3 Chitosan Hydrochloride 
(%W/V)
1
4 Sodium β 
Glycerophosphate (g)
4.12
5 Sodium Chloride (g) 0.5
6 Benzalkonium Chloride 
(ml)
0.02
7 Distilled Water (ml) Upto 100
 Formulation 2
● 
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The formulation 2 using  2 % chitosan hydrochloride as mentioned in the table was
prepared by dissolving the chitosan hydrochloride in the distilled water and cooling to
~40 C. 
●  The  pH was  lowered  by  1M HCl  To this  solution  sodium β-glycerophosphate
solution was added drop by drop with continuous stirring. 
●  To  the  chitosan  hydrochloride/glycerophosphate  solution  a  separately  prepared
solution of drug with hydroxy propyl β-cyclodextrin was added.  .
● Sodium chloride was added to maintain isotonicity. Finally benzalkonium chloride
was added and the volume was make up with distilled water. 
● The final pH of the formulation was adjusted to 6.8. 
● Each ingredient was separately sterilised by autoclaving at 1210C and 15 Psig for 20
minutes and added aseptically in laminar air flow work station. 
Table 7 : Composition of Formulation2 phase transition systems using Chitosan
hydrochloride
Sr no ingredients Quantity taken
1 Drug (g) 5
2 HP-β-CD (g) 5
3 Chitosan Hydrochloride 
(%W/V)
2
4 Sodium β 
Glycerophosphate (g)
8.25
5 Sodium Chloride (g) 0.5
6 Benzalkonium Chloride 
(ml)
0.02
7 Distilled Water (ml) Upto 100
 Evaluation of Formulations 
                
 Gelation Temperature 70,71
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The gelation temperature was estimated by heating the solution (about 1-20C/min) in a
test tube with gentle stirring until gel formed. Gel formation was taken as the point
when there was no flow, when the container was overturned. The temperature was
noted and designated as gel formation temperature.
Three replicates of each measurements was done and results were reproducible within
the range. Stirring speed and heating - cooling rates have no significant effect on the
transition temperature
 Viscosity Measurements 42,70,71,72,73,74 
For  the measurements  of  viscosity,  Brookfield  CAP Viscometer  was used. 1 to 2
drops of sample was placed on the temperature sensitive plate. All the parameters on
the instruments were fixed as per the instruction manual, then after some time the set
temperature  was  achieved.  Cone  No.  3  was  hold  on  the  plate  and  the  viscosity
readings were taken from the display of the instrument.  
 Rheological Behavior 75
To determine the type of flow, Brookfield CAP Viscometer was used. 1 to 2 drops of
sample  was  placed  on  the  temperature  sensitive  plate.  All  the  parameters  on  the
instruments were fixed as per the instruction manual, then after some time the set
temperature,  370C was achieved.  Cone No. 3 was hold on the plate and the shear
stress  and shear  strain  values  were  taken from the display of  the instrument.  The
rheograms of Formulations 1 and 2 were plotted.
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  Mucoadhesion Study  51,52,71,76,77,78
The bio- and mucoadhesion methods found in the literature are based on measuring
the force  required  to  break  the  adhesive  bond between  the  model  membrane and
adhesive.  Mucoadhesive force of nasal  phase transition system was determined by
means  of  the  mucoadhesive  force  measuring  device  shown  in  Figure  16  and
according to method adopted by (Yong,  et al.  2001and Elhady,  et al. 2003), using
porcine nasal mucosa and phosphate buffer saline as the moistening fluid. At the time
of testing, a section of tissue was secured, keeping the mucosal side out, on to each
glass vial using a rubber band and an aluminium cap. One vial with a section of tissue
was connected to the balance and other vial was kept in petridish. To the exposed
tissue on this vial, a constant amount of 0.5 gm polymer gel was applied. The height
of the vial was adjusted so that the gel could adhere to the mucosal tissues of both
vials. A constant force was placed on the upper vial and applied for two minutes, after
which it was removed and weights were added at a constant rate to the pan on the
other  side  of  the  modified  balance  of  the  used  device  until  the  two  vials  were
separated. The Mucoadhesive force, expressed as the detachment stress in dynes/cm2
was  determined from  the  minimal  weights  that  detached  the  two  vials  using  the
following equation.
                                                                m.g
                        Detachment stress =     -------- 
                              (Dynes/cm2)                A
                                                                 
 Where,
                        m: The weight added to balance in grams.
                         g:   Acceleration due to gravity taken as 980 cm/ sec2
                        A:  Area of the tissue exposed and is equal to pir2
                              (r- The radius of the circular hole in the aluminium cap).
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Figure 16: Mucoadhesive force measuring device, A-modified balance
B-weights, C- glass vial, D- polymer gel,
                       E-porcine nasal mucosa, F- support to vial to adjust height.
                      
   Duration of Mucoadhesion 71,79,80,81
This is an important factor in the formulation of bioadhesive dosage forms capable of
being retained on mucosal surfaces for extended period of time and must be given
careful consideration. Some test systems were designed to assess the effect of various
applied forces on the duration of mucoadhesion of the formulation 1 and 2, and to
consider  the  duration  of  adhesion  with  regard  to  the  adhesive  strength  of  these
materials.  
Method 1: This parameter was determined by a method modified from that of suzuki
et. al. (1985). An agar plate (containing agar at 1.5%w/v) of 7 cm in diameter was
prepared with pH 7.4 phosphate buffers. Five mg of the sample was placed on the
center  of  the agar  plate  and a circle  5 mm in diameter  was made.  The plate  was
slanted at 300 and the distance moved by the sample at 230 C was measured.
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Method 2: Duration of mucoadhesion of phase transition system was determined by
means  of  the  mucoadhesive  force  measuring  device  (Figure16) and  according  to
previously reported methods (Yong et.al. 2001 and Elhady, et al. 2003), using porcine
nasal  mucosa  and phosphate buffer  saline as  the moistening fluid.  At the  time of
testing a section of tissue (E) was secured, keeping the mucosal side out, onto each
glass vial(c) using a rubber band and an Aluminium cap. One vial with a section of
tissue was connected to the balance (A) and other vial was kept in petridish (F). To
the exposed tissue on this vial a constant amount of 0.5 g polymer gel (D) was applied
.The height of the vial was adjusted so that the gel could adhere to the mucosal tissues
of both vials.  A constant  force  was placed on the upper  vial  and applied for two
minutes, after which it was removed and weight of 10 g was added to the pan on the
other  side  of  the  modified  balance  of  the  used  device  until  the  two  vials  were
separated. Duration of mucoadhesion was noted as the time in hours taken to separate
two vials. 
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 In- Vitro Release Study 36,42,72,74,82
 In-vitro release study of the formulated phase transition system were carried out in
two chamber diffusion cell through dialysis membrane-70 (Himedia) with molecular
weight  cut  off  12000-14000  kDa.  Diffusion  cell  of  diameter  1.1  cm  and  22  ml
capacity consisted of upper cylindrical compartment open from above and diffusion
membrane at its base. To prepare artificial membrane, pieces of dialysis membrane
were soaked in phosphate buffer saline pH 7.4 for 24 hours before mounting on a
diffusion cell.
Diffusion membranes were mounted in a two chamber cells at 30 0C. Phase transition
system of  chitosan  hydrochloride  loaded  with  drug  were  placed  in  the  donor
compartment.  PBS  7.4,  100  ml  was  placed  in  the  receptor  compartment.  The
temperature of the receiver was maintained at 37 0C ± 1.0 0C during the experiment.
An aliquot of 1 ml was withdrawn from receiver compartment initially after 5, 15 and
30 minutes and then at 1-hour interval and replaced with same amount of medium.
Aliquots  so  withdrawn  were  suitably  diluted  and  analyzed  using  UV
spectrophotometer  at  274  nm for  drug.  In-vitro release  study was  carried  out  for
4 hours.  Table 21 shows the data of release profile  of drug from phase transition
system of chitosan hydrochloride and  Figure 17 shows release profile of drug from
phase transition system of chitosan hydrochloride.
         1)   Conc    = absorbance/slope
                          
          2) %release =   amount release/   label claim  x 100                                
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 In-Vitro Permeation Study 4,36,44,62,68,83,84
Tissue model
Excised nasal mucosa of different  species are frequently used tools to study nasal
transport and metabolism. Taking the difficulties into account to obtain human tissues
from  nasal  biopsies,  it  become  obvious  that  most  studies  were  performed  with
epithelia excise from animals. For majority of studies rabbit tissue has been used. In
this study porcine nasal mucosa obtained from local slaughterhouse has been chosen
as model membrane, mainly because of ready and economic availability in sufficient
quantity and reproducible quality
Tissue preparation
The skin around the nasal  region was removed and snout was separated from the
animal and opened up to expose the conchae. The mucosa covering the ventral nasal
conchae (cavity mucosa) was carefully removed using forceps and a scalpel.  After
being rinsed in saline solution and then distilled water, a piece of nasal mucosa was
mounted as flat sheet in a two chamber diffusion cells at 37  0C.  Formulations were
placed on mucosal surface in the donor compartment. Phosphate buffer pH 7.4 was
placed  in  receptor  compartment.  The  temperature  of  receiver  compartment  was
maintained at 37 0C ± 1 0C, during the experiment. 
An aliquot of 1 ml was withdrawn from receiver compartment initially after 5, 15 and
30 minutes and then at 1-hour interval and replaced with same amount of PBS 7.4.
Aliquots  so  withdrawn  were  suitably  diluted  and  analyzed  using  UV
spectrophotometer at 274 nm for drug. The in vitro permeation study was carried out
for  4  hours.  Data  showing  in-  vitro permeation  profile  of  drug  from  different
formulation through nasal membrane is mentioned in Table 26 and Figure 18, 19. The
permeability coefficient (P) was calculated using the following equation and values
are shown in Table 27
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       dQ/dt
P =   ---------
      Co.A
   Where:              
               
              dQ/dt :  Permeability rate
                Co:  Initial conc. in the donor chamber.
                A:  Effective surface area of mucosa.
 Drug Content 42,65,69
1 ml of the preparation was transferred to 1000 ml volumetric flasks with a pipette
and final volume was made up with phosphate buffer saline pH 7.4 absorbance was
recorded at 274 nm. The results for drug content was determined by using formula,
  % Drug content    =   absorbance x dilution factor x label claim x 100.
It contains not less than 90.0%and not more than 110.0% of the labeled amount of
pure drug.   
  Stability Study 88,89,90
Stability study was performed on formulation 1 and 2. The formulations were stored
at 10 0C ± 2 0C and 75% ± 5% Rh, 25 0C ± 2 0C and 75 % ± 5 % Rh and 40 0C ± 2 0C
and 75  % ± 5  % Rh,  for  a  period  of  3  months.  Formulations  were  evaluated  at
periodic  intervals  for  drug  content,  viscosity  and  gelation  temperature.  Data  for
stability study is shown in Table 15 and 16. 
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CH. VII.   
RESULTS AND DISCUSSION.
The drug  sample  was  characterized  on  the  basis  of  physicochemical  and  spectral
analysis to examine its authenticity. The results confirmed it to be the pure sample of
drug. 
The  polymer  chitosan  hydrochloride  was  also  characterized  on  the  basis  of
identification tests and confirmed to the reported values.
Scanning of  λmax  of drug by UV spectrophotometer
Scanning of drug by UV spectrophotometer showed λmax 274 nm and the standard
curve at 274 nm followed Beer-Lambert’s Law in the concentration ranging from 0-
60 µg/ml.
Drug polymer interaction study
Interaction  studies  were  performed  by  UV  scanning  and  FTIR  spectroscopy.  No
change in λmax of pure drug and drug containing polymeric solution was observed.
Drug free polymeric solution showed no absorption at 274 nm.
IR  spectra  of  drug  free  polymer  showed  no  matching  peaks  with  the  drug.  The
characteristic  peaks  of  the  drug  (1633,1245,1510,1184,805,820  cm-1)  was  found
same in the IR of the physical mixture of drug and chitosan hydrochloride.
Solubility of drug
Hydroxy propyl β-cyclodextrin was used to increase the solubility of drug in water
because of its property to form the inclusion complexes with a guest which results in
increased solubility of the drug. 
Formulation of phase transition system
For  the  formulation  of  phase  transition  system  chitosan  hydrochloride  and
glycerophosphate was used to prepare temperature triggered phase transition system.
Chitosan hydrochloride  and glycerophosphate  solution induces  hydrogel  formation
when  placed  at  physiological  temperature.  Chitosan  hydrochloride  precipitates  to
form hydrated  gel  above  pH 6.5.When  drug  is  added  it  increases  the  pH of  the
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solution and induces precipitation even before addition of complete addition of drug.
Thus temperature induced precipitation was aimed by adding beta glycerophosphate,
which keeps the chitosan in hydrated, solution form by getting incorporated between
the chitosan molecules and avoiding hydrophobic interaction at  lower temperature,
dehydration at higher temperature leads to geletion.
TABLES AND FIGURES.
Identification of drug :UV absorption spectroscopy
Figure8: UV Spectra of absorbance maxima of Drug in PBS 7.4
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Infra-red absorption spectroscopy: 
Figure9: Reference FTIR spectra of Drug
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Figure  10 : FTIR spectra of Drug sample
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 4.2. Analytical Methodology 56,57,64  
Observation :FTIR spectrum of drug was taken as shown in Figure10. 
The Characteristics peaks of the drug was found similar to that mentioned for
the reference spectra
Drug Polymer Interaction Study
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UV spectroscopy
Figure 11 :-UV spectra of drug A;Chitosan hydrochlofide soln;and Chitosan
hydrochlofide soln + drug
FTIR Spectroscopy
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B
A
C
Figure 12 :   FTIR Spectra of A :  drug,  
B: Chitosan hydrochloride, 
C : Physical Mixture of Drug and Chitosan hydrochloride 
Standard curve of drug
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Table 3 : Absorbance values of drug in PBS 7.4 at 274 nm.
Sr no conc.(µg/ml) Absorbance(nm)
1 10 0.05
2 20 0.098
3 30 0.147
4 40 0.193
5 50 0.245
6 60 0.298
Figure 13 :  Standard calibration curve of drug in PBS 7.4 at 274 nm.
EVALUATION OF FORMULATION.
The  developed  formulations  were  evaluated  for  percent  drug  content,  viscosity,
Mucoadhesion, duration of mucoadhesion, in vitro release, in vitro permeation, 
Gelation temperature
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Table 8: Gelation temperature of  Formulations 1 and  2
Viscosity Measurments
Table 9 : Viscosity of the Phase Transition System under increasing temperature
Temperature (0C) Viscosity (poise)
Formulation 1 Formulation 2
10 1.05  2.20 
25 1.40  2.46 
30 4.05  5.12 
31 5.23 6.30 
32 6.73  7.70 
33 8.93 9.89 
34 10.21 12.54 
35 12.70 14.05 
36 14.80 16.15 
37 15.85 17.20 
38 15.85 17.25 
39 15.90 17.26 
40 15.85 17.20 
Figure 14 :
 Viscosity of the Phase Transition System under increasing temperature
                                                                                                                             
                                                                                                                                    
 
Sr. No Formulations Gelation Temperature
(0C)
1 1 35-37
2 2 34-37
74
Rheological Behaviour
Figure 15A : Rheogram of Formulation 1
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Figure 15B: Rheogram of Formulation 2
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Mucoadhesion Study  
Table 14 : Mucoadhesive force of chitosan hydrochloride phase transition
system
  
                                                                                                                             
                                                                                                                                    
 
Sr. No Formulations Mucoadhesive force(dynes/cm2 x 102 )
1 1 24.63   ± 0.36
2 2 32.39  ± 0.42
76
Duration of Mucoadhesion
Table 15 : Movement of Formulation on Agar plate in cms.(method 1)
Formulations Time (Hr)
1 2 3 4 5 6
1 0.4 1.0 1.7 2.5 2.8 >3 
2 0.2 0.6 1.2 1.9 2.2 2.7 
Table 16 : Duration of Mucoadhesion by Method 2
In vitro release study 
Table 17: Data showing release profile of  plain drug solution through dialysis
membrane
Time(mins) Absorbance(nm) conc.(µg/ml) %release
5 0.012 0.24 1.2
15 0.0206 0.412 2.06
30 0.030 0.600 3.00
40 0.045 0.90 4.5
120 0.0648 1.296 6.48
                                                                                                                             
                                                                                                                                    
 
Sr. No Formulations Time (Hr)
1 1 4.05  
2 2 4.30  
77
180 0.0993 1.986 9.93
240 0.1047 2.094 10.47
                                                              Figure:17
          Graph showing the release profile of plain drug solution through dialysis
membrane
Table18 : Data showing release profile Formulation 0  through dialysis
membrane
        
Time(mins) Absorbance(nm) conc.(µg/ml) %release
5 0.0246 0.492 2.46
15 0.0436 0.872 4.36
30 0.0586 1.172 5.86±
40 0.0925 1.85 9.25
120 0.1364 2.728 13.64
180 0.1913 3.826 19.13
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240 0.2307 4.614 23.07
Figure 18 :
Graph showing the release profile of formulation 0 through dialysis membrane
Table19 : Data showing release profile Formulation 1through dialysis membrane
Time(mins) Absorbance(nm) conc.(µg/ml) %release
5 0.751 10502 7.51
15 0.1282 2.564 12.82
30 0.1884 3.768 18.84
40 0.2466 4.932 24.66
120 0.3023 6.046 30.23
180 0.3644 7.292 36.46
240 0.4020 8.04 40.20
                                                           Figure 19 : 
Graph showing the release profile of formulation 1through dialysis membrane 
from  phase transition system of chitosan hydrochloride.
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Table20: Data showing release profile Formulation 2 of through dialysis 
membrane  from  phase transition system of chitosan hydrochloride.
Time(mins) Absorbance(nm) conc.(µg/ml) %release
5 0.0844 1.688 8.44
15 0.1427 2.854 14.27
30 0.1990 3.98 19.90
40 0.2812 5.624 28.12
120 0.310 6.20 31.0
180 0.3729 7.458 37.29
240 0.4196 8.392 41.96
Figure 20 :Graph showing the release profile of formulation 2 through dialysis
membrane from  phase transition system of chitosan hydrochloride
                                                                                                                             
                                                                                                                                    
 
80
Table 21: Data showing release profile of drug through dialysis membrane from 
phase transition system of Chitosan Hydrochloride 
Time (min) Cumulative % drug released
Drug Solution Formulation 0 Formulation 1 Formulation 2
Time(mins) 1.12 2.46 7.51 8.44
Time(mins) 2.06 4.36 12.82 14.27
Time(mins) 3.0 5.86 18.84 19.90
Time(mins) 4.5 9.25 24.66 28.12
Time(mins) 6.48 13.64 30.23 31.0
Time(mins) 9.93 19.13 36.46 37.29
Time(mins) 10.47 23.07 40.20 41.96
Figure 21:
Release profile of drug through dialysis membrane from phase transition system
of Chitosan Hydrochloride
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In vitro permeation study
Table 22 :   Permeation profile of  plain drug solution through porcine nasal
membrane
Time(mins) Absorbance(nm) conc.(µg/ml) % drug
permeated
5 0.0212 0.424 2.12 
15 0.0348 0.696 3.48 
30 0.0483 0.966 4.83 
40 0.0772 1.544 7.72 
120 0.1047 20.94 10.47 
180 0.1368 2.736 13.68 
240 0.1546 3.092 15.46 
                                                          Figure 22 : 
Graph showing the permeation profile of plain drug solution through porcine
nasal membrane.
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Table  23  :   Permeation profile of Formulation 0 through porcine nasal
membrane
Time(mins) Absorbance(nm) conc.(µg/ml) % drug
permeated
5 0.0540 1.08 5.40
15 0.0652 1.304 6.52 
30 0.1128 2.256 11.28 
40 0.1634 3.268 16.34 
120 0.2132 4.264 21.
180 0.2712 5.424 27.12 
240 0.3156 6.312 31.56 
                                                            Figure 23 : 
Graph showing the permeation profile of formulation0 through porcine nasal
membrane
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                                                   Table 24   : 
 Permeation profile of Formulation 1 through porcine nasal membrane
Time(mins) Absorbance(nm) conc.(µg/ml) %drug permeated
5 0.1423 2.846 14.23 
15 0.1754 3.508 17.54 
30 0.2442 4.884 24.42 
40 0.3132 6.264 31.32 
120 0.3854 7.708 38.54 
180 0.4658 9.316 46.58 
240 0.5126 10.252 51.26 
                                                       Fig 24 : 
Graph showing the permeation profile of formulation1 through porcine nasal
membrane
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                                                  Table  25  :
 Permeation profile of Formulation 2 through porcine nasal membrane
Time(mins) Absorbance(nm) conc.(µg/ml) %drug
permeated
5 0.1570 3.14 15.70 
15 0.1842 3.684 18.42 
30 0.2656 4.884 26.56 
40 0.3312 6.264 33.12 
120 0.4016 80032 40.16 
180 0.4782 9.564 47.82 
240 0.5278 10.556 52.78 
                                                            Fig 25:
Graph showing the permeation profile of formulation2 through porcine nasal
membrane
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Table 26 : cumulative % of Drug permeated through porcine nasal membrane 
Time
(min)
Drug Solution  Formulation 0 Formulation 1 Formulation 2
5 2.12 5.40 14.23 15.70 
15 3.48 6.52 17.54 18.42 
30 4.83 11.28 24.42 26.56 
60 7.72 16.34 31.32 33.12 
120 10.47 21.32 38.54 40.16 
180 13.68 27.12 46.58 47.82 
240 15.46 31.56 51.26 52.78 
Figure 26 : cumulative % of drug permeated through porcine nasal membrane 
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          Table 27 : Permeability Coefficient of formulations 
Drug content
Table 27 : Drug content of formulated phase transition system
                                                                                                                             
                                                                                                                                    
 
Formulations Membrane
used
Permeability   
     coefficient (10 -6cm/sec)
Drug solution Nasal 3.68
 0 Nasal 7.19
1 Nasal 9.17
2 Nasal 9.27
87
Sr.
No
    Formulations Drug content (%)
1  0 99.82 
2 1 98.61 
3 2 98.14 
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Stability Studies
Table 28 : Evaluation of formulation 1 after different time interval at different
temperature
Temperature / Parameters
Evaluated
Storage
0 month 1 month 2 month 3 month
10 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.61 98.60 98.60 98.59 
Viscosity (P) 1.05 1.05 1.05 1.05 
Gelation
temperature ( 0C) 35-37 35-37 35-37 35-37
25 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.61 98.60 98.59 98.59 
Viscosity (P) 2.40 2.40 2.40 2.40 
Gelation
temperature(0C) 35-37 35-37 35-37 35-37
40 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.61 98.59 98.58 98.58 
Viscosity (P) 15.85 15.85 15.85 15.85 
Table 29 : Evaluation of formulation 2 after different time interval at different
temperature
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Temperature / Parameters
Evaluated
Storage
0 month 1 month 2 month 3 month
10 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.14 98.12 98.13 98.13 
Viscosity (P) 2.20 2.20 2.20 2.20 
Gelation
temperature (0C) 34-37 34-37 34-37 34-37
25 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.14 98.13 98.12 98.12 
Viscosity (P) 3.46 3.46 3.46 3.46 
Gelation
temperature(0C) 34-37 34-37 34-37 34-37
40 0C ± 2 0C
75 % ± 5 % Rh
Drug Content (%) 98.14 98.14 98.13 98.12 
Viscosity (P) 17.20 17.20 17.20 17.20 
Formulations showed good stability with no change in drug content,  viscosity and
gelation temperature after stability study of 3 months. 
DISCUSSION
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The  developed  formulations  were  evaluated  for  Gelation  Temperature, viscosity,
Mucoadhesion,  duration  of  mucoadhesion,  in  vitro release,  in  vitro permeation,
& percent  drug content.
Gelation Temperature  Gelation temperature observed for formulation 1 was in the
range of 35-37 0C and that of formulation 2 was in the range of 34-37 0C. Gelation
temperature is the temperature at which liquid phase makes transition to gel. Gelation
temperature range suitable would be  30-36 0C. 
If the gelation temperature is lower than 30 0C, gelation occurs at room temperature
leading to difficulty in administering .If the gelation temperature is higher than 36 0C,
it will leak out from the nasal cavity. Thus the suitable gelation temperature is 30-36
0C, to be a liquid form at room temperature and to form a gel  phase in the nasal
cavity. 
Viscosity Measurements 
The values of viscosity in poise for formulation 1 at 100C (1.05), 250C (2.40), 400C
(15.85)  and  that  of  formulation  2  at  100(2.20),  250(3.46)  and  400(17.20)  were
observed.  The  rise  in  viscosity  with  rise  in  temperature  may  be  because  of  the
formation of gel  as chitosan along with glycerophosphate on heating shows phase
transition. The addition of glycerophosphate salt to chitosan aqueous solution directly
modulates electrostatic  and hydrophobic interactions  (dehydration of chitosan with
increase  in  temperature  leads  to  increased  hydrophobic  interaction  between  the
molecules)  and  hydrogen  bonding  between  chitosan  chains,  which  are  the  main
molecular forces involved in the gel formation. This study supported by Chenite et al
Rheological behavior 
Rheological characteristics of formulation 1 and 2  was studied using Brookfield CAP
Viscometer and rheograms prove that both the formulations exhibited pseudoplastic
flow as evidence by shear thinning with the increase in speed of spindle.
Mucoadhesion study
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The formulations 1 and 2 were subjected to mucoadhesion study & the mucoadhesive
force  of  fromulation  1  was  observed  to  be  24.63  x  102   dynes/cm2  and  that  of
formulation 2 was found to be 32.39 x 102  dynes/cm2 . The mucoadhesive force is an
important  physicochemical  parameter  for  phase  transition  system  of  nasal
formulations since it prevent the gels from nasal clearance and increase the residence
time in the nasal cavity. 
The reinforcement of the mucoadhesive forces of the nasal phase transition system by
the use of mucoadhesive polymers could be explained by the fact that secondary bond
forming  groups  (hydroxyl,  ether,  oxygen  and  amine)  are  the  principle  source  of
mucoadhesion.  This  study is  supported  by Elhady et  al.  The  bioadhesive  force  is
known to depend on the nature and the concentration of bioadhesive polymers. With
the  increase  in  polymer  concentration  mucoadhesion  was  found  to  increase.  The
stronger the bioadhesive force more is the residence time in nasal cavity. But if the
bioadhesive force is too excessive the gel can damage nasal mucous membrane. 
Duration of mucoadhesion
Duration of mucoadhesion carried out by two different method shows the time that
the formulation can remain in contact with the membrane. The duration by  method 2,
for formulation 1 was 4.05 hrs. and for formulation 2 was 4.30 hrs. was found shorter
as compared to agar plate method i. e. method 1 (movement of formulation less than
3cm even  after  4  hrs).  This  may be  because  of  the  higher  stress  applied  on  the
formulation in case of  method 2 as compared to method 1.
In vitro release study
Formulations  were  subjected  to  in-  vitro  release  studies  using  synthetic  cellulose
nitrate  membrane,  at  370C.  Phosphate  buffer  saline  7.4  was  selected  as  diffusion
membrane. The % drug release by plain drug solution (10.47), formulation 0 (23.07),
formulation 1 (40.20) and formulation 2 (41.96) was calculated for 4 hours and is
mentioned in the  table.
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 In vitro permeation study
Permeability coefficient of drug solution through nasal membrane was  3.68 x 10–6
cm/sec. This may be because nasal membrane is comparatively very thin and may be
because it contains large number of pores, this is supported by the study of M. D.
Chavanpatil.
Permeability coefficient of drug solubilised by HP β cyclodextrin (7.19x10-6 cm/sec)
was even greater than plain drug therefore HP β cyclodextrin serves two purposes,
one increase the solubility of drug and second improves the permeability of the drug.
The formulation 1 and 2 show extremely significant (P<0.01) change in permeability
coefficient (9.17x10 –6 cm/sec for formulation 1 and 9.27x10-6 cm/sec for  CHT 2)
than plain drug, this may be because the formulation 1 and formulation 2 contain HP
β cyclodextrin along with chitosan hydrochloride, which shows synergistic effect on
the permeation of drug. Chitosan hydrochloride open up the tight junction and HP β
cyclodextrin extracts the phospholipids and proteins from membrane by forming a
new inclusion compartment  in  the  aqueous phase.  This  statement  is  supported  by
Shayun Yu and Zhang Q.
Drug Content 
The percent drug content of formulation 0 was found to be 99.82, formulation 1 found
to be 98.61 and that of formulation 2 was 98.14. The drug content of phase transition
system is shown in table.
The use of chitosan hydrochloride in phase transition system is substantiated by the
property  of  its  aqueous  solution  along  with  glycerophosphate  to  transform  into
hydrogel when the temperature is raised to physiological conditions demonstrated by
viscosity measurement. 
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CH. VIII.   
SUMMARY AND CONCLUSION
Nasal delivery is a feasible alternative to oral or parenteral administration for some
drugs because of the high permeability of the nasal epithelium rapid drug absorption
across this membrane and avoidance of hepatic first pass metabolism.
The nasal dosage form includes solution, sprays, microspheres, gels and liposomes.
Although solutions are easy to use they achieve a poor bioavailability, due to large
mucocilliary clearance. It  had been demonstrated that a significant improvement in
bioavailability would be achieved if the nasal residence time of the drug would be
increased. From the point of view of patient acceptability a liquid dosage form that
can be administered easily and can adhere to the nasal mucosa for extended period
with fast onset of action is ideal.
Drug delivery system based on the concepts of phase transition system should provide
these  properties,  such  delivery  system  show phase  transition  due  to  a  change  in
specific  physicochemical  properties  (pH,  Temperature,  Ionic  content)  in  their
environments.
In  the  present  work,  attempt  was  made  to  develop  phase  transition  system  with
mucoadhesive  properties  that  can  be  easily  administered  as  drops  and  attains
semisolid properties at physiological temperature at the site of absorption, improves
bioavailability giving fast onset of action with reduced dosing compared to oral drug
delivery. 
The formulation 1 and 2 containing 1% chitosan hydrochloride  and 2 % chitosan
hydrochloride respectively were subjected to various evaluation parameters.
For  both  the  formulations  marked  increase  in  viscosity  was  observed  when  the
temperature was raised upto 370C. From the duration of mucoadhesion study it was
found that both the formulations can adhere to the nasal mucosa at least for a period
of 4 hours. No significant differences in permeability coefficient were observed when
subjected to in vitro permeation study.
So, from the above observation the nasal permeation  and the retention time of drug
increases  by  the  addition  of  increasing  percentage  of  chitosan  in  both  the
formulation,and formulation 2 is considered as best formulation .
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CH. IX.  
FUTURE SCOPE
• In-vivo study  to  determine  pharmacokinetic  and  pharmacodynamic
parameters.
• Gel formation study in nasal cavity.
• Drug clearance study from nasal cavity.
 CH.X.
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